Aas_Study

Endomyocardial Fibrosis

2025-05-15T22:54:00.000+05:30

Endomyocardial Fibrosis

Endomyocardial fibrosis (EMF) is a rare but serious form of restrictive cardiomyopathy that primarily affects the endocardium and the innermost layer of the myocardium. It is characterised by progressive fibrosis—an excessive deposition of connective tissue—in one or both ventricles of the heart. This leads to a stiffening of the ventricular walls, impaired ventricular filling during diastole, and eventually congestive heart failure. Endomyocardial fibrosis predominantly occurs in tropical and subtropical regions, particularly in parts of sub-Saharan Africa, South Asia, and South America. Most commonly, it affects children and young adults, often resulting in chronic cardiac morbidity. While uncommon in developed countries, EMF continues to impose a considerable public health burden in endemic areas due to limitations in diagnostic infrastructure, low awareness, and insufficient access to therapeutic interventions.

Image source Google

Causes & Risk Factors

Although the definitive cause of endomyocardial fibrosis remains elusive, various environmental, infectious, and immunological factors have been implicated in its pathogenesis. Parasitic infections—particularly those involving helminths such as filarial worms and schistosomes—have been associated with hypereosinophilic syndromes, which are considered central to EMF development. Eosinophils, upon activation, release cytotoxic granules that incite inflammation and tissue damage, ultimately progressing to fibrosis. Nutritional deficiencies, especially of protein and micronutrients, have also been linked to EMF in low-resource settings. Genetic predisposition, autoimmune mechanisms, and chronic exposure to allergens are additional factors contributing to susceptibility. Social determinants such as poverty, poor sanitation, and limited access to healthcare exacerbate the risk, making EMF not only a medical but also a socioeconomic concern.

Pathogenesis

The pathogenesis of endomyocardial fibrosis unfolds through three interrelated stages. Initially, an acute inflammatory response, typically mediated by eosinophilic infiltration, damages the endocardial lining. This inflammation can be driven by parasitic antigens or autoimmunity. The second phase is thrombotic, where the inflamed endocardium serves as a nidus for thrombus formation, increasing the risk of embolic events. The final and most chronic phase is marked by progressive fibrosis, characterised by collagen deposition, endocardial thickening, and calcification. This pathophysiological sequence leads to obliteration of the ventricular apex and subvalvular regions, impairing diastolic filling and reducing stroke volume. As fibrosis becomes more extensive, the heart’s compliance decreases, resulting in a rigid, underperforming myocardium.

Symptoms & Signs

Patients with endomyocardial fibrosis often present with symptoms reflective of chronic heart failure, including progressive exertional dyspnoea, fatigue, and peripheral oedema. Right-sided EMF typically causes hepatomegaly, ascites, and lower limb swelling, whereas left-sided involvement is more likely to produce pulmonary congestion, orthopnoea, and paroxysmal nocturnal dyspnoea. Palpitations and chest discomfort are also common, with some patients experiencing atrial fibrillation due to atrial enlargement and endocardial scarring. In advanced cases, systemic embolisation resulting from mural thrombi may occur. On physical examination, clinicians may detect elevated jugular venous pressure, a third heart sound, murmurs indicating atrioventricular valve regurgitation, and signs of congestive hepatopathy. These clinical features underscore the importance of distinguishing EMF from other forms of cardiomyopathy and constrictive pericarditis.

Diagnosis

Diagnosing endomyocardial fibrosis requires an integrated approach combining clinical, imaging, and laboratory assessments:

Clinical History and Physical Examination – Initial evaluation should identify heart failure symptoms, risk exposures, and signs of right or left ventricular dysfunction.
Electrocardiogram (ECG) – May reveal low voltage QRS complexes, atrial enlargement, or arrhythmias such as atrial fibrillation.
Chest Radiography – Useful for assessing cardiomegaly, pulmonary congestion, and pleural effusions.
Transthoracic Echocardiography – Key diagnostic modality, revealing apical obliteration, endocardial thickening, and atrioventricular valve regurgitation.
Cardiac Magnetic Resonance Imaging (MRI) – Offers superior spatial resolution to delineate fibrotic tissue and assess ventricular function.
Endomyocardial Biopsy – Although invasive, it provides definitive histopathological confirmation, demonstrating fibrosis, eosinophilic infiltrates, and myocardial degeneration.
Laboratory Investigations – Include eosinophil count, serologic testing for parasitic infections, autoimmune markers, and inflammatory biomarkers.

Treatment

Effective management of endomyocardial fibrosis necessitates a comprehensive and individualised therapeutic plan:

Allopathic Management:
- Diuretics (e.g., Furosemide 20–80 mg/day) to relieve fluid overload and reduce symptoms.
- ACE Inhibitors (e.g., Enalapril 5–10 mg/day) to reduce afterload and improve cardiac output.
- Beta-blockers (e.g., Metoprolol 25–100 mg twice daily) for rate control and prevention of arrhythmias.
- Oral Anticoagulants (e.g., Warfarin 5 mg/day with INR monitoring) to prevent thromboembolism.
- Surgical Options: Endocardectomy and valve replacement may be beneficial in advanced or refractory cases.
Homeopathic Approach:
- Crataegus oxyacantha (Mother tincture, 10–15 drops in water thrice daily) to enhance myocardial tone.
- Digitalis purpurea (30C potency, twice daily) for improving myocardial contractility and controlling palpitations.
- Treatment duration typically spans 3–6 months, with adjustments based on clinical response.
Ayurvedic Therapy:
- Arjuna Churna (3–5 grams twice daily) as a cardiotonic.
- Punarnava Mandoor (250 mg twice daily post meals) to address oedema and renal support.
- Dashmool Kwath (15–30 ml twice daily) for its anti-inflammatory properties.
- Ayurvedic therapy should be continued for 6–9 months under qualified supervision.
Unani Remedies:
- Habb-e-Jadwar (1 tablet twice daily) to enhance cardiac function.
- Sharbat Aijaz (10 ml twice daily) to support circulatory and respiratory health.
- Duration typically ranges from 3 to 6 months, depending on patient response and clinical status.

Prevention

Preventing endomyocardial fibrosis hinges on addressing modifiable environmental and healthcare factors. Mass deworming campaigns, improved sanitation, and health education in endemic regions can significantly reduce the risk. Nutritional programmes aimed at alleviating protein and micronutrient deficiencies also play a preventive role. Early identification and management of parasitic infections are vital. Public health surveillance and community outreach are critical components in mitigating the incidence and burden of EMF.

Complications

Uncontrolled or poorly managed endomyocardial fibrosis can result in multiple serious complications:

Progressive congestive heart failure
Systemic embolisation due to intracardiac thrombi
Persistent atrial fibrillation and arrhythmias
Severe valvular regurgitation (mitral or tricuspid)
Impaired ventricular contractility
Sudden cardiac arrest
Secondary renal dysfunction due to chronic congestion
These complications underscore the necessity of early recognition and sustained, multidisciplinary management.

Prognosis

The prognosis for patients with endomyocardial fibrosis is largely determined by the stage at diagnosis and the adequacy of treatment. Early-stage disease, when detected and managed appropriately, may remain stable or even improve. However, in its advanced form, EMF is associated with a high risk of cardiac decompensation, arrhythmic events, and mortality. Surgical interventions, though potentially curative, carry substantial perioperative risks and are not universally available. Prognosis is generally poor in under-resourced settings due to delayed diagnosis and limited access to care.

Epidemiology

Endomyocardial fibrosis shows a striking regional distribution, with the highest prevalence reported in equatorial Africa, parts of India (especially Kerala and Tamil Nadu), Sri Lanka, and northeastern Brazil. In some African cardiology centres, EMF constitutes up to 20% of heart failure admissions. The disease tends to affect younger individuals, with a slight male predominance. Socially, patients often come from impoverished backgrounds with limited healthcare access, which complicates both diagnosis and treatment.

Research & Recent Advances

Recent scientific advancements have enhanced our understanding of the immunopathological mechanisms underlying endomyocardial fibrosis. The role of eosinophils, cytokines, and autoimmunity is being actively explored. Cardiac imaging has also evolved, with MRI and echocardiographic techniques such as speckle-tracking improving diagnostic precision. Genetic studies are investigating susceptibility loci and familial aggregation, potentially paving the way for predictive testing. Ongoing clinical trials in endemic regions aim to evaluate the efficacy of immunosuppressive agents, antifibrotic drugs, and novel surgical techniques. These developments offer promise for more effective disease-modifying strategies.

Case Studies

In a documented case from Kerala, a 14-year-old male presented with chronic breathlessness, hepatomegaly, and oedema. Echocardiography revealed right ventricular apical fibrosis and tricuspid regurgitation. Medical management with diuretics and anticoagulation led to symptom improvement. Another case in Nigeria involved a 25-year-old female who underwent successful endocardectomy and valve repair after presenting with refractory heart failure. These examples highlight the importance of timely, individualised treatment and the potential for clinical recovery.

Summary & Conclusion

Endomyocardial fibrosis represents a chronic, progressive form of restrictive cardiomyopathy prevalent in tropical climates. Although its aetiology remains multifactorial and incompletely understood, evidence supports a central role for eosinophilic inflammation, parasitic infections, and environmental influences. Diagnosis requires a combination of clinical evaluation, imaging, and histological confirmation. Management is complex and must be individualised, often integrating pharmacological, surgical, and complementary approaches. Preventive public health measures are critical in high-risk regions. Continued research is essential to unravel disease mechanisms, improve diagnostic tools, and expand therapeutic options. Raising awareness among healthcare professionals and policymakers is crucial to mitigating the impact of this under-recognised cardiovascular disorder.

References

Mocumbi AO. Endomyocardial fibrosis: a form of endemic restrictive cardiomyopathy. Clin Res Cardiol. 2008.
Davies JN. Endomyocardial fibrosis in Uganda. East Afr Med J. 1960.
Olsen EG. Endomyocardial disease: definitions and classification. Br Heart J. 1981.
Marijon E et al. Rheumatic and non-rheumatic valvular heart disease in Africa: a clinical perspective. Lancet. 2012.
Lobo RA, et al. MRI findings in endomyocardial fibrosis. Int J Cardiol. 2014.
Gnanaraj JP et al. Clinical and echocardiographic characteristics of endomyocardial fibrosis in South India. Indian Heart J. 2017.
Bukhman G et al. Clinical features and management of endomyocardial fibrosis: a review. Global Heart. 2019.

Endocardial Fibroelastosis

2025-04-13T20:06:00.005+05:30

Endocardial Fibroelastosis

Endocardial fibroelastosis (EFE) is an uncommon but potentially life-threatening cardiac condition that predominantly affects neonates and infants. It is defined by abnormal proliferation of fibrous and elastic connective tissue within the endocardium, primarily of the left ventricle, resulting in a thickened, less compliant myocardial lining. This histological alteration adversely impacts myocardial relaxation and contraction, culminating in compromised systolic and diastolic function. EFE may exist as an isolated idiopathic disorder or as a sequela of congenital cardiac anomalies. Prompt recognition and management are imperative to mitigate the risk of irreversible heart failure and mortality. This article presents a detailed exposition of EFE, encompassing its aetiology, pathophysiology, clinical manifestations, diagnostic modalities, therapeutic approaches across medical systems, epidemiological patterns, recent research developments, and illustrative case reports.

Image source Google

Causes & Risk Factors

EFE can be classified into primary (idiopathic) and secondary forms. Idiopathic EFE lacks a well-defined aetiology, though associations with genetic aberrations and intrauterine stressors have been proposed. Secondary EFE typically arises in the context of structural heart disease, such as aortic stenosis, hypoplastic left heart syndrome, or dilated cardiomyopathy. Prenatal infections, particularly viral agents like Coxsackie B virus and mumps, are implicated as teratogens that may induce EFE. Maternal-fetal immunological cross-reactivity, involving the transfer of autoantibodies, is another potential mechanism. Established risk factors include a positive family history of congenital cardiac anomalies, consanguinity, maternal infections during gestation, and syndromic conditions including Noonan and Barth syndromes.

Pathogenesis

The pathogenic cascade underlying EFE is characterised by hyperplasia of fibroblasts and excessive deposition of collagen and elastin within the endocardial layer. This results in increased endocardial stiffness and impaired ventricular compliance, particularly during diastole. The myocardium becomes increasingly inefficient, with compromised preload accommodation and reduced stroke volume. In cases secondary to congenital malformations, chronic intracavitary pressure elevations may incite a reactive fibrotic response. Genetic contributions include mutations in TAZ and LAMP2 genes, which affect mitochondrial and lysosomal function, respectively. Contemporary research also explores oxidative stress, immune dysregulation, and mitochondrial dysfunction as contributory mechanisms.

Image source Google

Symptoms & Signs

Clinical presentation of EFE is often nonspecific in early stages, necessitating a high index of suspicion. Infants commonly exhibit signs of congestive heart failure, including tachypnoea, dyspnoea during feeding, poor weight gain, lethargy, diaphoresis, and hepatomegaly. Auscultatory findings may include a gallop rhythm, systolic murmurs, or displaced apex beat. Progressive disease may result in cyanosis, peripheral oedema, and signs of systemic venous congestion. Due to the overlap with other cardiac or respiratory conditions, diagnostic delays are not uncommon, especially in resource-limited settings.

Diagnosis

Diagnostic evaluation involves a multi-modal, tiered approach:

History and Physical Examination – Thorough assessment for familial cardiac history, antenatal exposures, and clinical signs.
Echocardiography – First-line modality showing hyperechogenic endocardium, reduced ventricular function, and chamber dilatation.
Electrocardiography (ECG) – May indicate left ventricular hypertrophy, ST-T changes, and conduction delays.
Chest Radiography – Demonstrates cardiomegaly, pulmonary congestion, and altered cardiac silhouette.
Cardiac Magnetic Resonance Imaging (MRI) – Offers detailed characterisation of myocardial fibrosis and structural anomalies.
Genetic Analysis – Considered when familial clustering or syndromic features are present.
Endomyocardial Biopsy – Invasive procedure reserved for ambiguous cases to confirm histological diagnosis.

Treatment

Management strategies encompass conventional pharmacological interventions and complementary therapies drawn from traditional systems:

Allopathic Interventions:

Digoxin: 0.01–0.05 mg/kg/day orally; enhances myocardial contractility.
Furosemide: 1–2 mg/kg/day; diuretic effect reduces preload.
Captopril: 0.1–0.5 mg/kg/dose administered 2–3 times daily; mitigates afterload.
Carvedilol: Initiated at low doses; provides β-blockade to reduce myocardial oxygen demand.
Cardiac Transplantation: Considered in refractory end-stage cardiac failure.

Homeopathic Protocols:

Crataegus oxyacantha (Mother tincture or 3x): Cardiac tonic; dosed twice daily for 3–6 months.
Digitalis purpurea (6C–30C): Indicated for arrhythmias and breathlessness; administered once daily under supervision.

Ayurvedic Modalities:

Arjuna (Terminalia arjuna): 500–1000 mg twice daily; improves cardiac output.
Dashamoola Kwatha: 10–15 ml twice daily; supports systemic circulation.
Hridayarnava Rasa: Used judiciously for cardiac tonification; supervised usage for 6–9 months.

Unani Therapies:

Sharbat Aroosa: 10 ml post-meals; promotes myocardial strength.
Habbe Jadwar: One tablet daily; traditional cardiotonic.
Laooq-e-Katan: Adjunct for respiratory distress; administered over 3–6 months.

Prevention

Preventive strategies target antenatal and perinatal health optimisation. Routine prenatal screening, maternal vaccination (e.g., rubella), and avoidance of teratogenic substances are critical. Genetic counselling for at-risk families enhances early risk identification. Nutritional support, prompt infection management, and avoidance of consanguineous marriages may further reduce incidence rates.

Complications

If inadequately managed, EFE can precipitate a cascade of severe sequelae:

Chronic congestive heart failure
Intractable arrhythmias
Left ventricular non-compaction
Sudden cardiac death
Recurrent lower respiratory tract infections
Neurodevelopmental delays due to chronic hypoperfusion

Prognosis

Prognosis is contingent on early diagnosis, therapeutic responsiveness, and disease severity. Patients receiving early, multidisciplinary care generally exhibit improved cardiac function and survival rates. However, delayed intervention often results in irreversible myocardial fibrosis and increased mortality. Advances in paediatric heart failure management and transplantation are progressively enhancing outcomes.

Epidemiology

EFE is an infrequent entity, with incidence estimates below 1 per 100,000 live births. Male infants are more frequently affected. Although globally distributed, prevalence may vary due to genetic, environmental, and diagnostic discrepancies. Increasing awareness and accessibility to echocardiography have led to higher detection rates in recent years.

Research & Recent Advances

Emerging investigations focus on elucidating the molecular and genetic basis of EFE. Identified mutations in TAZ and LAMP2 genes hint at metabolic and lysosomal pathway disruptions. Research into foetal echocardiographic markers, non-invasive biomarkers, and molecular diagnostics is ongoing. Gene-editing techniques like CRISPR and regenerative therapies, though in early stages, offer potential future therapeutic avenues. Stem cell-based myocardial regeneration is also under preliminary exploration.

Case Studies

UK Infant (6 months) – Presented with failure to thrive and dyspnoea. Diagnosed via echocardiogram and MRI; managed with digoxin and Arjuna; six-month follow-up showed marked improvement.
Indian Siblings (2 and 4 years) – Both diagnosed with EFE. Genetic predisposition suspected. Treated with a combination of allopathic and Unani medicines. Serial echocardiography indicated clinical stability.
Prenatal US Case – Diagnosed in utero using foetal echocardiography. Postnatal intervention initiated immediately. Cardiac function preserved with multidisciplinary support.

Summary & Conclusion

Endocardial fibroelastosis represents a rare paediatric cardiomyopathy characterised by fibrous thickening of the endocardium, resulting in impaired ventricular compliance and heart failure. A nuanced understanding of its diverse aetiologies, symptomatology, and pathophysiology is essential for timely diagnosis and intervention. Multimodal therapies spanning allopathic and traditional systems provide comprehensive management options. With evolving diagnostics and targeted research, the prognosis for affected individuals continues to improve. Preventive public health strategies and early recognition remain pivotal to reducing disease burden.

References

Hoffman JI. “The Natural and Unnatural History of Congenital Heart Disease.” Wiley-Blackwell, 2009.
Towbin JA et al. “Endocardial Fibroelastosis: A Review.” Cardiology in the Young, 2014.
American Heart Association. “Pediatric Cardiomyopathies.” 2022.
WHO. “Congenital Heart Defects: Global Overview.” 2021.
Indian Journal of Paediatrics. “Integrative Approaches in Paediatric Heart Conditions.” 2020.
British Heart Foundation. “Understanding Rare Heart Conditions in Children.” 2023.
European Society of Cardiology. “Paediatric Heart Failure Management Guidelines.” 2021.

You should also know about

Cardiac Amyloidosis

2025-03-27T23:14:00.002+05:30

Cardiac Amyloidosis: An In-Depth Analysis

Cardiac amyloidosis is a progressive and life-threatening disorder characterised by the deposition of misfolded amyloid fibrils within the myocardium. This pathological protein accumulation results in increased myocardial stiffness, diastolic dysfunction, and, ultimately, heart failure. Due to its nonspecific clinical manifestations, cardiac amyloidosis often remains undiagnosed until advanced stages, highlighting the necessity for heightened clinical awareness and improved diagnostic methodologies.

Image source Google

Aetiology and Risk Factors

Cardiac amyloidosis primarily manifests in two distinct forms:

Light Chain (AL) Amyloidosis: Originates from clonal plasma cell dyscrasia, wherein monoclonal light chains misfold and aggregate as amyloid fibrils in various organs, including the heart.
Transthyretin (ATTR) Amyloidosis: Arises due to misfolding of the transthyretin (TTR) protein. This can occur as a result of hereditary mutations (hATTR) or age-related destabilisation of wild-type TTR (wtATTR).

Key risk factors include genetic predisposition, chronic inflammatory conditions, multiple myeloma, and advancing age. Epidemiological studies indicate that wtATTR amyloidosis is particularly prevalent in elderly populations, whereas specific TTR mutations disproportionately affect individuals of African and Portuguese descent.

Pathophysiology

The pathogenesis of cardiac amyloidosis involves extracellular deposition of amyloid fibrils within myocardial tissue, disrupting normal cardiac architecture and function. These fibrillar aggregates impair cardiomyocyte contractility, diminish ventricular compliance, and lead to restrictive cardiomyopathy. Furthermore, amyloid deposition interferes with electrical conduction pathways, predisposing patients to arrhythmias and conduction abnormalities. Over time, these pathophysiological changes culminate in progressive heart failure with preserved ejection fraction (HFpEF).

Image source Google

Clinical Presentation

The symptomatology of cardiac amyloidosis is highly variable and often mimics other cardiovascular diseases. Key clinical features include:

Exercise intolerance and exertional dyspnoea
Peripheral oedema and ascites due to right heart failure
Orthostatic hypotension resulting from autonomic dysfunction
Atrial fibrillation and conduction disturbances
Carpal tunnel syndrome, particularly in ATTR amyloidosis
Unintentional weight loss and fatigue

Diagnostic Approach

Accurate and timely diagnosis of cardiac amyloidosis necessitates a multimodal approach incorporating imaging, biomarker analysis, and histological confirmation:

Echocardiography: Demonstrates ventricular hypertrophy with preserved ejection fraction, apical sparing on strain imaging, and restrictive physiology.
Cardiac Magnetic Resonance (CMR) Imaging: Utilised for tissue characterisation, revealing late gadolinium enhancement with a global subendocardial pattern indicative of amyloid infiltration.
Nuclear Scintigraphy: Differentiates ATTR from AL amyloidosis, with technetium-labelled bone tracers showing avidity for ATTR deposits.
Serum and Urine Free Light Chain Assays: Essential for ruling out AL amyloidosis.
Endomyocardial Biopsy: Considered the gold standard, with Congo red staining demonstrating apple-green birefringence under polarised light.
Genetic Testing: Recommended for suspected hereditary ATTR amyloidosis to guide familial risk assessment and management.

Therapeutic Strategies

Treatment modalities for cardiac amyloidosis are contingent upon the underlying aetiology:

AL Amyloidosis:
- Chemotherapy (e.g., bortezomib, daratumumab) targets clonal plasma cells.
- Autologous stem cell transplantation (ASCT) may be considered in select patients.
ATTR Amyloidosis:
- TTR stabilisers (e.g., tafamidis) prevent protein misfolding and slow disease progression.
- Gene silencing therapies (e.g., patisiran, inotersen) reduce hepatic TTR synthesis.
- Liver transplantation remains an option for hereditary ATTR amyloidosis.
Supportive Measures:
- Diuretics for volume management
- Pacemaker implantation for conduction disturbances
- Exercise and dietary modifications for symptom control

Prevention and Risk Reduction

While genetic predisposition renders some cases unavoidable, early intervention and lifestyle modifications may mitigate disease progression. Regular cardiovascular screening in at-risk populations facilitates early diagnosis, and emerging pharmacotherapies offer hope for disease-modifying interventions.

Disease Complications

Without appropriate treatment, cardiac amyloidosis precipitates severe complications, including:

Progressive heart failure and cardiogenic shock
Ventricular arrhythmias and sudden cardiac death
Systemic thromboembolism and cerebrovascular events
Multi-organ involvement, particularly renal and hepatic dysfunction

Prognosis

The prognosis of cardiac amyloidosis varies based on the underlying subtype and treatment response. AL amyloidosis, if untreated, has a particularly poor prognosis with a median survival of approximately six months post-diagnosis. However, early intervention with chemotherapy or stem cell transplantation can significantly improve outcomes. ATTR amyloidosis, especially wtATTR, progresses more slowly, with survival often exceeding a decade when managed effectively with disease-modifying therapies such as tafamidis. Early diagnosis and appropriate management are critical in enhancing patient survival and quality of life.

Epidemiological Trends

Recent advances in diagnostic techniques have led to increased recognition of cardiac amyloidosis. AL amyloidosis primarily affects individuals in their 60s, whereas wtATTR amyloidosis is increasingly diagnosed in patients over 70 years of age. With improved awareness and genetic screening, hereditary forms of ATTR amyloidosis are being detected at earlier stages, allowing for timely therapeutic intervention.

Recent Advances in Research

Ongoing clinical trials are exploring novel therapeutic strategies aimed at halting or reversing amyloid deposition. Gene-editing technologies such as CRISPR hold promise for directly modifying pathogenic TTR mutations, while small-molecule inhibitors are being investigated for their role in disrupting amyloid fibril aggregation. Advances in biomarker research are also facilitating early-stage detection, improving prognostic outcomes.

Case Studies

Case Study 1: AL Amyloidosis

A 62-year-old male presented with progressive dyspnoea and neuropathy. Echocardiography demonstrated increased left ventricular wall thickness, and serum free light chain assays confirmed AL amyloidosis. Chemotherapy with bortezomib led to significant haematological response and symptom stabilisation.

Case Study 2: ATTR Amyloidosis

A 70-year-old female with bilateral carpal tunnel syndrome and autonomic dysfunction was diagnosed with ATTR amyloidosis via nuclear scintigraphy. Genetic testing revealed a pathogenic TTR mutation. Tafamidis therapy was initiated, leading to symptomatic improvement and stabilisation of disease progression.

Conclusion

Cardiac amyloidosis is an increasingly recognised cause of heart failure with preserved ejection fraction. Advances in diagnostic imaging, biomarker assays, and targeted therapies have transformed disease management, offering patients improved survival and quality of life. Continued research into disease pathophysiology and novel therapeutics remains crucial for optimising patient outcomes.

References

Wechalekar, A. D., et al. (2016). "Systemic amyloidosis." The Lancet, 387(10038), 2641-2654.
Gillmore, J. D., et al. (2018). "Nonbiopsy diagnosis of cardiac transthyretin amyloidosis." Circulation, 138(6), 599-609.
Maurer, M. S., et al. (2019). "Cardiac amyloidosis: JACC state-of-the-art review." Journal of the American College of Cardiology, 74(22), 2872-2885.
Ruberg, F. L., & Berk, J. L. (2020). "Transthyretin (ATTR) amyloidosis: Mechanisms and diagnosis." The Journal of the American College of Cardiology, 75(22), 2846-2861.
Hanna, M. (2021). "Novel therapies in cardiac amyloidosis." Circulation: Heart Failure, 14(2), e007973.

You should also know about

Dilated Cardiomyopathy

2025-03-23T18:49:00.001+05:30

Idiopathic Dilated or Congestive Cardiomyopathy: A Comprehensive Guide

Idiopathic dilated or congestive cardiomyopathy is a heart condition that weakens and enlarges the heart muscle, impairing its ability to pump blood effectively. In simple terms, it’s like the heart becoming overstretched and losing its strength, making it harder for the body to receive the oxygen-rich blood it needs. Globally, idiopathic dilated or congestive cardiomyopathy affects millions, with estimates suggesting it accounts for approximately 25% of all cases of heart failure. Its significance lies in its profound impact on life expectancy and quality of life. Patients with idiopathic dilated or congestive cardiomyopathy often face challenges such as fatigue, shortness of breath, and even sudden cardiac arrest if left untreated. Understanding this disease is crucial for early detection and effective management.

Image source Google

Types and Classification

While idiopathic dilated or congestive cardiomyopathy is primarily categorised as a single entity, variations exist based on symptoms, progression, and underlying causes. Some patients may experience milder forms where only specific chambers of the heart are affected, while others develop severe dilation across the entire organ. Additionally, certain subtypes may involve genetic mutations, though these are less common. The term "idiopathic" implies that no clear cause can be identified, but variations in presentation highlight the complexity of idiopathic dilated or congestive cardiomyopathy. For instance, some individuals may have minimal symptoms for years before progressing to advanced stages, whereas others may deteriorate rapidly.

Causes and Risk Factors

The exact cause of idiopathic dilated or congestive cardiomyopathy remains unknown, hence the term "idiopathic." However, researchers suspect a combination of genetic predispositions, environmental triggers, infections, and lifestyle factors play a role. Risk factors include advancing age, male gender, a family history of heart disease, poor diet, smoking, excessive alcohol consumption, and exposure to toxins. Viral infections, such as myocarditis, can also trigger idiopathic dilated or congestive cardiomyopathy in susceptible individuals. Stress and autoimmune disorders further compound the risks, underscoring the multifactorial nature of this condition. Recognising these risk factors is vital for prevention and early intervention.

Pathophysiology

At the core of idiopathic dilated or congestive cardiomyopathy lies a cascade of cellular and tissue-level changes within the heart. Initially, the heart muscle stretches excessively, leading to thinning and weakening of the walls. This structural damage disrupts the heart's pumping mechanism, causing inefficient blood circulation throughout the body. Over time, inflammation and fibrosis (scarring) exacerbate the dysfunction, worsening the prognosis of idiopathic dilated or congestive cardiomyopathy. The heart compensates by enlarging further, creating a vicious cycle that ultimately results in heart failure. Understanding these mechanisms helps clinicians devise targeted therapies to slow disease progression.

Signs and Symptoms

Early warning signs of idiopathic dilated or congestive cardiomyopathy often go unnoticed due to their subtlety. Fatigue, mild shortness of breath, and occasional palpitations might be dismissed as normal ageing or stress-related issues. As the condition progresses, more pronounced symptoms emerge, including persistent coughing, swelling in the legs and abdomen, and difficulty breathing when lying down. Severe cases of idiopathic dilated or congestive cardiomyopathy can lead to chest pain, fainting spells, and fluid retention, necessitating immediate medical attention. Differentiating between mild, moderate, and severe presentations aids in tailoring treatment plans for optimal outcomes.

Diagnosis

Diagnosing idiopathic dilated or congestive cardiomyopathy involves a thorough evaluation using various tools and techniques. Physicians typically begin with a physical examination to assess heart sounds, fluid retention, and overall health status. Blood tests, electrocardiograms (ECGs), echocardiograms, and cardiac MRIs are commonly employed to visualise the heart's structure and function. In some cases, a biopsy may be required to rule out other conditions mimicking idiopathic dilated or congestive cardiomyopathy. Challenges arise from overlapping symptoms with diseases like coronary artery disease or valvular heart disorders, emphasising the need for precise diagnostic protocols.

Stages or Progression

Idiopathic dilated or congestive cardiomyopathy is a chronic, progressive condition that advances through distinct stages. Early-stage patients may exhibit minimal symptoms despite underlying heart dysfunction. Moderate stages involve noticeable limitations in daily activities due to fatigue and breathlessness. Advanced stages are characterised by severe heart failure, requiring intensive medical or surgical interventions. Left untreated, idiopathic dilated or congestive cardiomyopathy can culminate in irreversible damage or death. Monitoring progression closely allows healthcare providers to adjust treatments accordingly.

Treatment Options

Managing idiopathic dilated or congestive cardiomyopathy involves a multidisciplinary approach combining medications, surgeries, and lifestyle modifications. Common medications include beta-blockers, ACE inhibitors, diuretics, and anticoagulants to alleviate symptoms and improve heart function. In severe cases, implantable devices like pacemakers or defibrillators may be necessary. Surgical options such as heart transplantation offer hope for end-stage patients. Lifestyle changes—such as adopting a low-sodium diet, engaging in light exercise, quitting smoking, and moderating alcohol intake—are integral to slowing disease progression. Supportive therapies like physiotherapy and counselling enhance overall well-being.

Complications

Untreated idiopathic dilated or congestive cardiomyopathy poses significant risks, ranging from arrhythmias and blood clots to kidney failure and liver damage. Long-term complications include pulmonary hypertension and recurrent hospitalisations due to worsening heart failure. These complications not only threaten survival but also diminish the patient's quality of life. Timely intervention is critical to mitigating these adverse outcomes associated with idiopathic dilated or congestive cardiomyopathy.

Prognosis

With appropriate treatment, the prognosis for idiopathic dilated or congestive cardiomyopathy varies depending on individual factors such as age, severity, and comorbidities. While complete recovery is rare, many patients achieve stable health with medication and lifestyle adjustments. Survival rates depend heavily on adherence to prescribed therapies and regular follow-ups. Younger patients without additional health issues tend to fare better than older adults with multiple ailments. Regular monitoring ensures timely interventions, improving long-term outcomes.

Prevention

Preventing idiopathic dilated or congestive cardiomyopathy centres around reducing modifiable risk factors. Maintaining a healthy weight, eating a balanced diet rich in fruits and vegetables, exercising regularly, and avoiding tobacco and excessive alcohol consumption are key strategies. Regular check-ups enable early detection, allowing for prompt action before symptoms escalate. Vaccinations against viral infections linked to cardiomyopathy, such as influenza and COVID-19, provide added protection. Though not always preventable, these measures significantly lower the risk of developing idiopathic dilated or congestive cardiomyopathy.

Living with the Disease

Living with idiopathic dilated or congestive cardiomyopathy requires resilience and adaptability. Patients benefit from joining support groups where they can share experiences and gain emotional support. Counselling services help address anxiety, depression, and the psychological toll of chronic illness. Managing daily life involves prioritising rest, pacing activities, and fostering open communication with loved ones about needs and limitations. Caregivers also require guidance to navigate the complexities of supporting someone with idiopathic dilated or congestive cardiomyopathy effectively.

FAQs

Q: Is idiopathic dilated or congestive cardiomyopathy curable?

A: Unfortunately, there is no cure, but treatments can manage symptoms and improve quality of life.

Q: Is it hereditary?

A: In some cases, yes. Genetic testing can determine familial links.

Q: What are the first signs?

A: Early signs include fatigue, shortness of breath, and palpitations.

Q: Can it be prevented?

A: While not entirely preventable, adopting a healthy lifestyle reduces risk.

Q: What happens if I ignore the symptoms?

A: Ignoring symptoms can lead to severe complications, including heart failure and death.

Conclusion

In summary, idiopathic dilated or congestive cardiomyopathy is a complex yet manageable condition affecting countless lives worldwide. Early diagnosis, tailored treatment, and proactive management hold the key to enhancing longevity and well-being. If you suspect any symptoms related to idiopathic dilated or congestive cardiomyopathy, don’t hesitate to consult a healthcare professional. Your heart deserves the best care possible.

Obstructive Cardiomyopathy

2025-03-22T18:29:00.001+05:30

Obstructive Cardiomyopathy: A Comprehensive Overview

Hypertrophic Obstructive Cardiomyopathy (HOCM) is a subtype of hypertrophic cardiomyopathy characterized by abnormal thickening of the myocardium, predominantly affecting the interventricular septum. This hypertrophy can impede blood flow from the left ventricle into the aorta, posing significant hemodynamic challenges. HOCM is a relatively rare disorder, with a prevalence of approximately 1 in 500 individuals, yet its implications for cardiovascular health are profound. Understanding the condition requires a multidisciplinary approach, encompassing insights from genetics, imaging, and interventional cardiology to ensure accurate diagnosis and effective management.

Image source Google

Pathophysiology

The pathophysiological hallmark of obstructive cardiomyopathy is asymmetric septal hypertrophy, which narrows the left ventricular outflow tract (LVOT) and disrupts normal hemodynamics. The resultant obstruction generates increased intraventricular pressure, which can provoke systolic anterior motion (SAM) of the mitral valve leaflets, further contributing to LVOT obstruction and mitral regurgitation. As the hypertrophied myocardium becomes less compliant, diastolic dysfunction ensues, leading to impaired ventricular filling. Over time, chronic pressure overload may result in myocardial fibrosis, which increases the risk of arrhythmias and sudden cardiac death. Genetic mutations, particularly in sarcomeric proteins such as beta-myosin heavy chain (MYH7) and myosin-binding protein C (MYBPC3), underpin most cases of HOCM, leading to aberrant myocardial structure and function.

Etiology and Risk Factors

HOCM is primarily an autosomal dominant genetic disorder, with variable penetrance and expression. Key risk factors include:

Genetic Predisposition: Mutations in genes encoding sarcomeric proteins are the most common cause.
Age: Symptoms typically manifest in adolescence or early adulthood but may present later in life.
Sex: Males may present with more pronounced hypertrophy, though the condition affects both sexes.
Exercise: High-intensity activities can exacerbate symptoms and increase the risk of sudden cardiac events.
Family History: First-degree relatives of affected individuals have a 50% chance of inheriting the genetic mutation.
Other Factors: Obesity, hypertension, and metabolic syndrome can further contribute to disease progression.

Clinical Manifestations

The clinical presentation of HOCM is diverse, ranging from asymptomatic cases to severe heart failure. Common symptoms include:

Exertional Dyspnea: Difficulty breathing during physical activity due to increased LVOT obstruction.
Angina Pectoris: Chest pain resulting from myocardial oxygen demand exceeding supply.
Syncope: Transient loss of consciousness, often precipitated by exertion or arrhythmias.
Palpitations and Arrhythmias: Sensation of irregular heartbeats due to underlying electrical disturbances.
Fatigue and Reduced Exercise Tolerance: Secondary to impaired cardiac output and diastolic dysfunction. In some cases, patients may remain asymptomatic, and the condition is only detected during routine screening or family evaluations.

Diagnostic Evaluation

A thorough diagnostic workup is crucial for identifying HOCM and assessing disease severity:

Physical Examination: Detection of a harsh systolic murmur, often accentuated with Valsalva maneuver, is suggestive of LVOT obstruction.
Echocardiography: Gold standard for visualizing septal hypertrophy, LVOT obstruction, and mitral valve anomalies. Doppler studies provide insights into pressure gradients across the outflow tract.
Electrocardiography (ECG): May reveal left ventricular hypertrophy, Q waves, or arrhythmias.
Cardiac MRI/CT: Provides detailed myocardial characterization, assessment of fibrosis, and delineation of myocardial architecture.
Genetic Testing: Identifies pathogenic mutations, aiding in family screening and risk stratification.
Exercise Stress Testing: Evaluates exertional symptoms and the presence of inducible LVOT obstruction.
Holter Monitoring: Assesses for paroxysmal arrhythmias, particularly in patients with palpitations or syncope.

Complications

Without proper management, HOCM can lead to severe complications, such as:

Sudden Cardiac Death: Particularly in young athletes, due to lethal arrhythmias.
Progressive Heart Failure: Resulting from diastolic dysfunction and elevated filling pressures.
Life-Threatening Arrhythmias: Including ventricular tachycardia and fibrillation.
Mitral Valve Dysfunction: Contributing to further hemodynamic instability and exacerbation of symptoms.
Infective Endocarditis: Rare but possible, due to turbulent blood flow across abnormal structures.

Therapeutic Approaches

Management strategies for HOCM aim to alleviate symptoms and reduce the risk of sudden cardiac death:

Pharmacologic Therapy: Beta-blockers and calcium channel blockers mitigate symptoms by reducing myocardial contractility and heart rate. Disopyramide may be used to reduce obstruction.
Invasive Interventions:
- Septal Myectomy: Surgical removal of hypertrophic septal tissue to relieve LVOT obstruction.
- Alcohol Septal Ablation: Induces localized myocardial infarction to reduce septal thickness.
- Implantable Cardioverter-Defibrillator (ICD): Prevents sudden cardiac death in high-risk patients.
Lifestyle Modifications: Restriction from competitive sports and strenuous activities. Avoiding dehydration and maintaining electrolyte balance are also crucial.

Long-Term Management and Prognosis

Long-term care involves periodic monitoring of cardiac function and symptom progression. Risk stratification for sudden cardiac death is crucial and involves assessing factors like family history, extent of hypertrophy, and prior arrhythmic events. The prognosis is highly variable, influenced by genetic factors, the degree of hypertrophy, and adherence to treatment regimens. Many patients can achieve a normal lifespan with appropriate medical and surgical management, though some may require heart transplantation in refractory cases.

Preventative Measures

Preventing adverse outcomes in HOCM requires a multifaceted approach:

Regular cardiovascular screening for first-degree relatives.
Genetic counseling for at-risk families.
Adoption of heart-healthy behaviors, such as maintaining optimal blood pressure, avoiding excessive physical exertion, and adhering to prescribed therapies.
Awareness programs aimed at recognizing warning signs early, especially in athletic populations.

Coping with HOCM

Living with HOCM demands not only physical adaptation but also emotional resilience. Accessing psychosocial support, engaging with patient advocacy groups, and staying informed about emerging therapies can empower individuals to navigate their condition more effectively. Patients should be encouraged to maintain an active dialogue with their healthcare providers and participate in shared decision-making regarding treatment options.

Conclusion

Obstructive cardiomyopathy is a complex genetic disorder with profound implications for cardiovascular health. Advances in diagnostic modalities and therapeutic interventions have greatly improved patient outcomes. Early diagnosis, tailored treatment strategies, and ongoing research remain pivotal in enhancing the quality of life for affected individuals. As understanding of the condition continues to evolve, future therapies hold promise for even better management and prognosis.

References

Maron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. (2014). Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine. Journal of the American College of Cardiology, 64(1), 83-99.
Elliott, P. M., Anastasakis, A., Borger, M. A., Borggrefe, M., Cecchi, F., Charron, P., ... & Watkins, H. (2014). 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 35(39), 2733-2779.
Ho, C. Y., & Seidman, C. E. (2006). A contemporary approach to hypertrophic cardiomyopathy. Circulation, 113(24), e858-e862.

Inflammation

2025-03-18T17:27:00.001+05:30

Inflammation: Etiology, Pathophysiology, Clinical Manifestations, and Evidence-Based Interventions

Inflammation constitutes a complex biological response to noxious stimuli, encompassing infection, tissue injury, and immune dysregulation. While acute inflammation is integral to tissue homeostasis and repair, persistent or dysregulated inflammation has been implicated in the pathogenesis of numerous chronic diseases, including cardiovascular disease, metabolic disorders, and autoimmune conditions. This article elucidates the multifactorial causes of inflammation, delineates its clinical presentation, and examines both natural and medical modalities for mitigating its adverse sequelae.

Image source Google

Pathophysiology of Inflammation

Inflammation is initiated by the activation of pattern recognition receptors (PRRs) on innate immune cells, such as macrophages and neutrophils, in response to pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). This activation triggers intracellular signaling cascades, culminating in the release of pro-inflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and C-reactive protein (CRP).

Two principal types of inflammation have been delineated:

Acute Inflammation: This transient response is characterized by the classical cardinal signs of rubor (redness), tumor (swelling), calor (heat), dolor (pain), and functio laesa (loss of function). The acute phase typically resolves upon eradication of the inciting agent and tissue repair.
Chronic Inflammation: Prolonged activation of inflammatory pathways leads to sustained cytokine production, tissue remodeling, and fibrosis. Chronic inflammation contributes to pathological states such as atherosclerosis, insulin resistance, and neurodegeneration.

Image source Google

Etiological Factors

Multiple exogenous and endogenous stimuli can precipitate an inflammatory response:

Infectious Agents: Bacterial endotoxins, viral antigens, and fungal components provoke innate immune activation.
Tissue Injury: Mechanical trauma or ischemia-reperfusion injury initiates sterile inflammation.
Autoimmune Pathologies: Aberrant immune responses against self-antigens perpetuate chronic inflammation.
Nutritional Factors: Diets enriched in refined carbohydrates, saturated fats, and processed foods exacerbate inflammatory pathways.
Psychological Stress: Persistent activation of the hypothalamic-pituitary-adrenal (HPA) axis augments systemic inflammation.
Environmental Exposures: Pollutants, tobacco smoke, and industrial chemicals serve as pro-inflammatory stimuli.

Clinical Manifestations

Inflammatory processes manifest variably depending on acuity and etiology:

Acute Inflammation: Presents with localized erythema, edema, hyperthermia, nociception, and functional impairment.
Chronic Inflammation: May elicit nonspecific systemic symptoms such as fatigue, subfebrile temperatures, gastrointestinal dysregulation, cachexia, arthralgia, and cognitive decline.

Disease Associations

Persistent inflammation is a cardinal contributor to a spectrum of chronic conditions:

Cardiovascular Disease: Vascular inflammation accelerates atherogenesis and plaque instability.
Type 2 Diabetes Mellitus: Chronic inflammation disrupts insulin signaling, fostering insulin resistance.
Rheumatoid Arthritis: Autoimmune-mediated synovitis leads to joint destruction and systemic complications.
Neurodegenerative Disorders: Microglial activation and neuroinflammation are implicated in cognitive decline.
Oncogenesis: Chronic inflammatory states promote cellular proliferation, genomic instability, and angiogenesis.

Evidence-Based Strategies for Modulating Inflammation

Mitigation of chronic inflammation necessitates multifaceted interventions:

Nutritional Interventions:
- Incorporate polyphenol-rich foods such as berries, leafy greens, and cruciferous vegetables.
- Prioritize omega-3 fatty acids from marine sources to counteract pro-inflammatory eicosanoids.
Physical Activity: Engaging in regular aerobic exercise modulates inflammatory markers and enhances metabolic resilience.
Psychological Interventions: Mindfulness-based stress reduction (MBSR) techniques mitigate stress-induced inflammatory cascades.
Sleep Hygiene: Ensuring adequate and restorative sleep downregulates inflammatory mediators.
Environmental Modifications: Minimize exposure to air pollutants, tobacco smoke, and industrial toxins.

Pharmacological Interventions

In cases of pronounced inflammation, pharmacotherapeutic interventions may be warranted:

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Inhibit cyclooxygenase (COX) enzymes, attenuating prostaglandin synthesis.
Corticosteroids: Suppress gene transcription of pro-inflammatory cytokines via glucocorticoid receptor-mediated mechanisms.
Biologics: Monoclonal antibodies targeting TNF-α, IL-6, or IL-1 have revolutionized treatment paradigms in autoimmune diseases.

Preventative Strategies

Adoption of anti-inflammatory lifestyle practices is pivotal:

Embrace a Mediterranean-style diet replete with phytochemicals and monounsaturated fats.
Maintain a healthy body mass index (BMI) through regular physical activity.
Optimize hydration status.
Minimize exposure to environmental toxins and adopt stress-reduction practices.

Conclusion

Inflammation represents a sophisticated and indispensable physiological response. Nonetheless, its chronic dysregulation underpins a multitude of pathological states. Integrating evidence-based nutritional strategies, physical activity, stress management, and judicious pharmacologic interventions can modulate inflammatory processes, fostering optimal health outcomes. Personalized medical consultation is essential to tailoring interventions to individual inflammatory profiles.

Encephalitis

2025-03-05T04:48:00.002+05:30

Encephalitis

Synonyms

Brain Inflammation
Acute Viral Encephalitis
Infectious Encephalitis
Autoimmune Encephalitis
Cerebral Infection
Neuroinflammation

Introduction and Definition

Encephalitis is a severe, often life-threatening, inflammatory condition of the brain, typically resulting from viral infections, autoimmune reactions, or, in rarer cases, bacterial and fungal pathogens. The pathological hallmark of encephalitis is extensive neuroinflammation leading to neuronal dysfunction, cerebral edema, and, in severe cases, irreversible neurological sequelae. Given the heterogeneity in etiology and clinical presentation, accurate and timely diagnosis is imperative to optimize therapeutic interventions and reduce morbidity and mortality.

Historical Context and Origin

The etymology of encephalitis is derived from the Greek words enkephalos (brain) and itis (inflammation). Early descriptions of encephalitic syndromes can be traced back to Hippocratic medical texts. However, modern medical characterization gained significant attention during the 1916 epidemic of encephalitis lethargica, which underscored its potential for widespread neurological devastation. Since then, substantial progress in neurovirology, immunopathology, and molecular diagnostics has facilitated precise identification of causative agents and targeted therapeutic approaches.

Essential Anatomy and Physiological Considerations

The pathophysiology of encephalitis implicates critical anatomical structures and physiological processes:

Cerebral Cortex: Cognitive deficits, seizures, altered consciousness
Limbic System (including the Hippocampus): Memory impairment, behavioral disturbances
Brainstem: Autonomic dysfunction, respiratory failure
Meninges and Blood-Brain Barrier (BBB): Disruption allows pathogenic infiltration
Basal Ganglia: Movement abnormalities, dystonia
Neurovascular Unit: Inflammatory damage may compromise cerebrovascular integrity

Classification of Encephalitis

Infectious Encephalitis
- Viral: Herpes simplex virus (HSV), West Nile virus, Rabies, Enteroviruses, Cytomegalovirus (CMV)
- Bacterial: Tuberculous encephalitis, Listeria monocytogenes, Syphilitic encephalitis
- Fungal: Cryptococcus neoformans, Aspergillus spp.
- Parasitic: Toxoplasma gondii, Naegleria fowleri
Autoimmune Encephalitis
- Anti-NMDA receptor encephalitis
- Hashimoto’s encephalopathy
Metabolic/Toxic Encephalitis
- Hepatic encephalopathy, uremic encephalopathy
- Lead, mercury, and other heavy metal toxicity
Paraneoplastic Encephalitis
- Associated with systemic malignancies
Post-Infectious (Para-Infectious) Encephalitis
- Measles-associated subacute sclerosing panencephalitis (SSPE)
Chronic/Recurrent Encephalitis
- Rasmussen’s encephalitis

Pathophysiological Mechanisms

Pathogen Entry: Hematogenous dissemination or retrograde axonal transport
Immune Activation: Cytokine-mediated neuroinflammation
Neuronal Injury: Direct viral cytotoxicity and immune-mediated demyelination
Cerebral Edema: Raised intracranial pressure, risk of herniation
Sequelae: Seizures, cognitive impairment, persistent neurological deficits

Clinical Manifestations

Key Signs and Symptoms

Pyrexia with constitutional symptoms
Altered mental status (confusion, disorientation, somnolence, coma)
Focal or generalized seizures
Neuromuscular deficits (paresis, aphasia, ataxia)
Photophobia, meningismus (if concurrent with meningitis)
Psychiatric symptoms (hallucinations, catatonia, agitation)
Speech and memory disturbances

Diagnostic Modalities

Clinical Evaluation: Neurological assessment, cognitive function testing
Laboratory Workup: CBC, inflammatory markers, autoimmune panels
Cerebrospinal Fluid (CSF) Analysis: Elevated protein, lymphocytic pleocytosis
Neuroimaging:
- MRI: Hyperintense lesions in the medial temporal lobe (HSV encephalitis)
- CT scan: Cerebral edema, hemorrhagic changes
Electroencephalography (EEG): Diffuse slowing, epileptiform activity
Molecular and Serological Testing: PCR for viral DNA/RNA, autoantibody panels
Brain Biopsy (in select cases): Histopathological confirmation

Differential Diagnosis and Comparative Analysis

A detailed table differentiating infectious, autoimmune, toxic, and metabolic encephalitic presentations can be provided based on clinical and diagnostic features.

Multimodal Management Approach

Allopathic Intervention

Supportive Therapy: Hemodynamic stabilization, ventilatory support
Antiviral Regimen: Acyclovir (10 mg/kg IV q8h, 14-21 days for HSV)
Immunomodulation: Corticosteroids, intravenous immunoglobulins (IVIG), plasma exchange
Seizure Prophylaxis: Levetiracetam, benzodiazepines
Empirical Antibacterial/Fungal Coverage: Based on CSF microbiology

Complementary and Alternative Medicine

Homeopathic Remedies

Belladonna 30C: Neuroinflammation and fever
Apis Mellifica 30C: Cerebral edema
Gelsemium 200C: Post-viral neurological sequelae

Unani Medicine

Sharbat Unnab: Detoxification
Roghan Kadu: Neuroprotection
Khamira Abresham: Cognitive enhancement

Nutritional and Adjunctive Therapy

Hydration and electrolyte maintenance
Omega-3 fatty acids, B-vitamin-rich foods
Anti-inflammatory components (curcumin, flavonoids)

Surgical Considerations

Decompressive craniectomy (for intractable cerebral edema)

Potential Complications

Chronic neurological deficits
Epilepsy
Coma, mortality

Recent Advances in Research

Monoclonal Antibodies: Rituximab, Tocilizumab in autoimmune encephalitis
AI-Driven Diagnostics: Machine learning-based neuroimaging analysis

Conclusion

Encephalitis represents a complex neuroinflammatory disorder with diverse etiological underpinnings. Recent advances in diagnostic modalities, immunotherapy, and artificial intelligence are improving patient outcomes and broadening the therapeutic landscape.

References

Tyler KL. "Emerging viral encephalitides." Nature Medicine (2018)
Granerod J, et al. "Encephalitis: Clinical presentations and management." The Lancet Neurology (2017)
Venkatesan A, Murphy OC. "Autoimmune encephalitis: Pathophysiology and treatment." Neurology (2020)
Misra UK, Kalita J. "Viral encephalitis management." Journal of Neurology (2019)
WHO. "Guidelines on encephalitis diagnosis and management." (2021)

Hyperbilirubinemia

2025-02-04T18:30:00.002+05:30

Jaundice

Also known as Icterus, Hyperbilirubinemia, Yellow discoloration syndrome, Bilirubin metabolic disorder, Peeliya (local term)

Introduction

Jaundice is a complex clinical syndrome characterized by the yellow discoloration of the skin, sclerae, and mucous membranes due to elevated serum bilirubin levels exceeding 2 to 3 mg/dL. Bilirubin, a tetrapyrrolic bile pigment, is formed during the catabolism of heme derived from senescent erythrocytes. The condition signals an underlying disorder in bilirubin metabolism, transport, or excretion, often linked to pre-hepatic, hepatic, or post-hepatic etiologies.

Historical Context

The recognition of jaundice can be traced back to ancient civilizations. It was meticulously documented in Egyptian papyri and addressed in Hippocratic writings. The term "jaundice" is derived from the French word "jaune," meaning yellow. Early interpretations attributed it to humoral imbalances. With advancements in hepatology, molecular biology, and imaging technology during the 19th and 20th centuries, our understanding of bilirubin metabolism and its pathological manifestations significantly improved.

Essential Anatomy and Physiology

Liver: The central organ for bilirubin metabolism, where hepatocytes uptake unconjugated bilirubin and conjugate it with glucuronic acid via UDP-glucuronosyltransferase for excretion.
Biliary System: Comprising intrahepatic and extrahepatic bile ducts, gallbladder, and sphincter of Oddi, essential for bile and bilirubin transport.
Spleen: Plays a pivotal role in erythrocyte turnover and heme release.
Kupffer Cells: Hepatic macrophages responsible for degrading hemoglobin into biliverdin, a precursor of bilirubin.
Enterohepatic Circulation: Facilitates bile salt and bilirubin metabolite reabsorption, maintaining bilirubin homeostasis.

Types or Classification

Pre-hepatic Jaundice: Caused by excessive hemolysis, resulting in increased unconjugated bilirubin.
Hepatic Jaundice: Impaired hepatic uptake, conjugation, or excretion of bilirubin due to liver diseases such as hepatitis and cirrhosis.
Post-hepatic (Obstructive) Jaundice: Bile duct obstructions prevent bilirubin excretion.

Pathophysiology

Pre-hepatic: Increased erythrocyte lysis leads to unconjugated hyperbilirubinemia.
Hepatic: Hepatocyte dysfunction compromises bilirubin uptake and conjugation, resulting in mixed hyperbilirubinemia.
Post-hepatic: Biliary obstruction causes reflux of conjugated bilirubin into systemic circulation.

Causes of intrahepatic and extrahepatic jaundice

Clinical Features

Yellow skin and sclera: Hallmark of elevated bilirubin.
Dark urine: Indicates high conjugated bilirubin.
Acholic stools: Suggests bile duct obstruction.
Pruritus: Common in cholestatic jaundice.
Systemic symptoms: Include malaise, anorexia, and abdominal discomfort.

Cardinal Signs and Symptoms

Scleral Icterus: Early indicator of jaundice.
Dark urine and pale stools: Hallmark of obstructive jaundice.
Hepatomegaly: Suggestive of liver disease.
Pruritus: Due to bile salt deposition.

Diagnostic Approach

Clinical Evaluation: Thorough history and physical examination.
Laboratory Investigations:
- Bilirubin Levels: Total, direct, and indirect bilirubin assays.
- Liver Function Tests (LFTs): ALT, AST, ALP, and GGT.
- Hemolysis Markers: LDH, haptoglobin, and reticulocyte count.
Imaging Modalities:
- Ultrasound: Detects biliary obstruction.
- CT and MRI: Provides detailed anatomical visualization.
- MRCP: Non-invasive biliary tree imaging.
Histopathology: Liver biopsy for definitive hepatic jaundice diagnosis.

Differential Diagnosis

Carotenemia: Yellow skin without scleral involvement.
Gilbert’s Syndrome: Benign hereditary hyperbilirubinemia.
Viral Hepatitis: Hepatic inflammation with elevated transaminases.
Primary Biliary Cirrhosis: Autoimmune cholestatic liver disease.
Drug-Induced Liver Injury (DILI): Hepatotoxicity from medications.

Comparative Analysis of Jaundice Types

Feature	Pre-Hepatic	Hepatic	Post-Hepatic
Etiology	Hemolysis	Liver disease	Bile duct obstruction
Bilirubin Type	Unconjugated	Mixed	Conjugated
Stool Color	Normal	Pale	Pale
Urine Color	Normal	Dark	Dark
Pruritus	Rare	Common	Severe

Therapeutic Management

Allopathic Medicine

Pre-hepatic:
- Blood transfusions for severe anemia.
- Glucocorticoids for autoimmune hemolysis.
Hepatic:
- Antiviral Therapy: Tenofovir (300 mg daily) for chronic hepatitis B.
- Immunosuppressants: Prednisolone for autoimmune hepatitis.
- Liver Transplant: For end-stage cirrhosis.
Post-hepatic:
- ERCP: Bile duct stenting.
- Cholecystectomy: Gallstone removal.
- Oncological Surgery: Tumor resection.

Homeopathic Medicine

Chelidonium majus: 30C, three times daily for biliary disorders.
Carduus marianus: 6X potency for hepatic detoxification.
Nux Vomica: 30C for associated gastrointestinal complaints.

Unani Medicine

Sharbat Banafsha: 10 ml twice daily for liver detox.
Jawarish Jalinoos: 5 grams after meals.
Majun Dabidul Ward: 5 grams twice daily for liver inflammation.
Arq Mako: 125 ml twice daily.

Dietary Recommendations

Include:
- Antioxidant-rich foods (berries, green tea).
- Hydration with coconut water and herbal teas.
- Low-fat dairy and whole grains.
Avoid:
- Alcohol, fried foods, and red meat.
- Processed foods high in preservatives.

Adjunctive Therapies

Phototherapy: Standard for neonatal jaundice.
Ayurvedic Panchakarma: Liver detox procedures.
Acupuncture: Symptom alleviation.

Surgical Interventions

Cholecystectomy: For gallbladder stones.
Biliary Stenting: To alleviate ductal obstruction.
Liver Transplant: For irreversible hepatic failure.
Tumor Resection: Oncological indications.

Clinical features and complications of cholestatic jaundice

Complications

Progression to chronic liver disease.
Hepatic encephalopathy.
Coagulopathy and bleeding disorders.
Biliary cirrhosis.
Acute renal failure.
Sepsis in cholestatic jaundice.

Recent Advances

Emerging treatments in gene therapy and regenerative medicine show promise for conditions underlying jaundice. Advances in artificial liver support systems are undergoing clinical trials. Additionally, bile acid-binding agents have demonstrated efficacy in managing pruritus associated with cholestatic jaundice. Biomarker research is improving diagnostic precision and personalized therapy.

Summary

Jaundice, indicative of bilirubin metabolic dysregulation, necessitates a multidisciplinary approach encompassing diagnosis, medical, surgical, and supportive therapies. Recent innovations in therapeutic strategies hold promise for enhancing clinical outcomes.

References

Friedman, L. S., & Keeffe, E. B. (2014). Handbook of Liver Disease. Elsevier.
Sherlock, S., & Dooley, J. (2011). Diseases of the Liver and Biliary System. Wiley-Blackwell.
Mayo Clinic. "Jaundice Overview." Retrieved from www.mayoclinic.org.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). "Liver Disease Information." www.niddk.nih.gov.
WHO Guidelines for Hepatitis and Liver Disease Management. www.who.int.
Kumar, P., & Clark, M. (2017). Clinical Medicine. Elsevier.

Stomach inflammation

2025-01-31T21:01:00.001+05:30

Gastritis

Also known as Stomach inflammation, Gastric mucosal inflammation, Gastric irritation. Gastritis refers to the inflammation, irritation, or erosion of the gastric mucosa (the lining of the stomach). It can occur suddenly (acute gastritis) or gradually over time (chronic gastritis). The condition may be caused by various factors, including infections, medications, or autoimmune disorders.

History

The term "gastritis" originates from the Greek words "gastro" meaning stomach and "-itis" indicating inflammation. Descriptions of gastric ailments date back to ancient Egypt and Greece. Modern medical understanding of gastritis began in the 19th century with advancements in pathology and gastroenterology.

Types/Classifications

Acute Gastritis:
- Sudden onset and short duration
- Often caused by infections or medications
Chronic Gastritis:
- Long-standing inflammation
- Divided into three types:
  - Type A (Autoimmune)
  - Type B (Bacterial, commonly Helicobacter pylori)
  - Type C (Chemical or Reactive)
Erosive Gastritis:
- Causes visible damage to the stomach lining
Non-erosive Gastritis:
- Inflammation without erosion
Special Types:
- Radiation-induced gastritis
- Lymphocytic gastritis
- Eosinophilic gastritis

Pathophysiology

Gastritis occurs when the protective mucous barrier of the stomach is compromised, allowing gastric acids to damage the underlying tissue. This leads to inflammation, swelling, and mucosal injury. In chronic gastritis, persistent inflammation can lead to atrophy, intestinal metaplasia, and even gastric cancer.

Common causes of Gastritis

Factors influencing H. pylori

Clinical Features

Cardinal Signs and Symptoms

Epigastric pain or burning sensation
Nausea and vomiting
Loss of appetite
Bloating and belching
Indigestion (dyspepsia)
Hematemesis (vomiting blood) in severe cases
Black or tarry stools

Diagnosis

Medical History and Physical Examination:
- Assessment of symptoms and potential triggers
Endoscopy:
- Visual examination of the stomach lining
Biopsy:
- Histological examination to assess inflammation
Laboratory Tests:
- H. pylori testing (breath, stool, or biopsy)
- Complete blood count (CBC)
Imaging Studies:
- Barium swallow radiographs (in selected cases)

Differential Diagnosis

Peptic ulcer disease
Gastroesophageal reflux disease (GERD)
Zollinger-Ellison syndrome
Functional dyspepsia
Gastric cancer
Pancreatitis

Comparison Table of Gastritis Types

Type	Onset	Cause	Features	Diagnosis
Acute	Sudden	Infection, NSAIDs, alcohol	Severe epigastric pain	Endoscopy
Chronic A	Gradual	Autoimmune	Anemia, vitamin B12 deficiency	Autoantibody test
Chronic B	Gradual	H. pylori	Nausea, dyspepsia	H. pylori test
Chronic C	Gradual	Bile reflux, drugs	Mild symptoms	History & endoscopy
Erosive	Sudden	Stress, alcohol	Hematemesis	Endoscopy

Treatment/Management

Allopathic Medicine

Proton Pump Inhibitors (PPIs): Omeprazole 20 mg/day for 4-8 weeks
H2 Receptor Blockers: Ranitidine 150 mg twice daily for 4 weeks
Antacids: Aluminum hydroxide as needed
Antibiotics (for H. pylori): Amoxicillin 1g twice daily + Clarithromycin 500 mg twice daily for 14 days
Mucosal Protectants: Sucralfate 1g four times daily for 4 weeks

Homeopathic Treatment

Nux Vomica 30C: 3 times daily for 7 days (for gastritis from overeating or alcohol)
Arsenicum Album 30C: Twice daily for 5 days (for burning pain and vomiting)
Carbo Veg 30C: 3 times daily for bloating

Unani Medicine

Habbe Asgand: 500 mg twice daily for 4 weeks
Sharbat Anar: 20 ml before meals
Safoof-e-khabsul hadeed: 1 tsp with honey twice daily

Diet Plan

Recommended:
- Bland foods like oatmeal and bananas
- Lean proteins
- Probiotic-rich foods (yogurt)
- Herbal teas (chamomile, ginger)
Avoid:
- Spicy and acidic foods
- Caffeinated beverages
- Alcohol and carbonated drinks

Therapies

Stress Management: Yoga, meditation
Acupuncture: To relieve gastric symptoms

Surgical Options

Rare but may include partial gastrectomy in severe cases of atrophic or erosive gastritis

Complications

Peptic ulcers
Gastric bleeding
Gastric cancer
Pernicious anemia
Gastric outlet obstruction

Recent Updates

New research highlights the role of microbiota in gastritis management.
Development of vaccines targeting H. pylori is underway.
Novel PPIs with improved bioavailability are in clinical trials.

Summary

Gastritis is a common gastrointestinal condition characterized by inflammation of the stomach lining. Its management involves lifestyle modifications, dietary changes, and medication. Proper diagnosis and timely treatment can prevent complications and improve the quality of life.

References

Everhart, J. E., & Ruhl, C. E. (2009). Burden of digestive diseases in the United States. Gastroenterology, 136(1), 91-101.
Marshall, B. J., & Warren, J. R. (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. The Lancet, 323(8390), 1311-1315.
Chey, W. D., & Wong, B. C. (2007). Treatment of Helicobacter pylori infection. The American Journal of Gastroenterology, 102(8), 1808-1825.
Talley, N. J., & Ford, A. C. (2015). Functional dyspepsia. New England Journal of Medicine, 373(19), 1853-1863.
Malfertheiner, P., Megraud, F., & O'Morain, C. A. (2017). Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report. Gut, 66(1), 6-30.

Body fluids

2025-01-30T21:33:00.003+05:30

Body Fluids

Body fluids are essential for maintaining physiological balance and enabling various biochemical processes within the body. These fluids exist within cells, surrounding tissues, and in specialized compartments, playing a critical role in transportation, lubrication, temperature regulation, and waste elimination.

Types of Body Fluids and Their Distribution

Body fluids are generally categorized into intracellular and extracellular fluids:

Intracellular Fluid (ICF): This fluid is contained within the cells and makes up about 60-65% of the total body fluid.
Extracellular Fluid (ECF): Comprising about 35-40% of the total body fluid, ECF is divided into:

Interstitial Fluid: Surrounds the cells and makes up around 75% of the ECF.
Plasma: The liquid component of blood, accounting for 20% of the ECF.
Transcellular Fluid: Found in specialized compartments such as cerebrospinal fluid, synovial fluid, and aqueous humor.

Distribution of body fluids

Physiology and Composition of Body Fluids

1. Intracellular Fluid (ICF)

Physiology: Maintains cell structure, supports biochemical reactions, and regulates cellular processes.
Composition: High concentrations of potassium (K+), magnesium (Mg2+), phosphate (PO4), and proteins. Low sodium (Na+) concentration.

2. Extracellular Fluid (ECF)

a) Interstitial Fluid

Physiology: Provides a medium for nutrient and waste exchange between blood and cells.
Composition: High in sodium (Na+) and chloride (Cl-) ions; low potassium (K+) levels.

b) Plasma

Physiology: Transports nutrients, hormones, and waste products throughout the body.
Composition: Contains water, electrolytes (Na+, Cl-, Ca2+, K+), plasma proteins (albumin, globulin, fibrinogen), glucose, and metabolic waste products.

c) Transcellular Fluid

Physiology: Plays specialized roles depending on the compartment, such as cushioning the brain, lubricating joints, and facilitating digestion.
Composition: Varies according to function; cerebrospinal fluid has a high sodium and low protein content, while synovial fluid contains lubricating proteins and electrolytes.

Recent Updates on Body Fluid Research

Recent advancements in body fluid research have focused on diagnostic and therapeutic applications:

Liquid Biopsy: Advances in analyzing extracellular fluids, such as plasma and cerebrospinal fluid, for cancer diagnosis and monitoring.
Electrolyte Imbalances: Improved understanding of the impact of fluid imbalances on chronic diseases like hypertension and kidney disorders.
Microfluidics Technology: Development of wearable sensors to monitor body fluid composition in real-time for personalized medicine.
Artificial Body Fluids: Progress in engineering synthetic body fluids for use in laboratory experiments and clinical applications.

References

Guyton, A.C., & Hall, J.E. (2016). Textbook of Medical Physiology. Elsevier.
Boron, W.F., & Boulpaep, E.L. (2017). Medical Physiology: A Cellular and Molecular Approach. Elsevier.
Stookey, J.D. (2005). Advances in body fluid research: Physiological and clinical applications. American Journal of Clinical Nutrition.
Recent advancements in liquid biopsy and microfluidics research (Accessed via PubMed and Nature Journals).

Overview of neoplasm

2024-11-05T18:17:00.003+05:30

Definition

A mass of tissue formed as a result of abnormal, excessive, uncoordinated, autonomous, and purposeless proliferation of cells even after removal of stimulus.

Neoplasm is a term while neoplasia is a process.
Tumour have two components, one is parenchyma (neoplastic cell) and second is stroma (supporting cells and vessels).

Limitations of definition -

In most of the cases growth persists after removal of stimuli.
In lot of cases we may not be able to recognize initiating stimuli.

Difference between Neoplasia and Hyperplasia
Features	Neoplasia	Hyperplasia
Proliferation	Uncontrolled	Under controlled
Coordination with surrounding tissue	Uncoordinated	Coordinated
Proliferation after removal of stimulus	Persists	Stop
Differentiation	Varies	Well-differentiated

CLASSIFICATION

Classification of tumour on the basis of type of origin:

The suffix '-oma' is added to the end of the word denote benign tumour such as lipoma, fibroma, myxoma etc. but their are some exceptions also available such as haematoma, granuloma (both are not a tumour), hamartoma and choristoma. There is one thing remember adenoma derived from gland but may or may not show glandular structure e.g. tumour of the adrenal gland or cortex and renal tubular cell these are glandular origin but may or may not show glandular structure.

Malignant tumours of epithelial origin are called carcinomas, while mesenchymal origin of malignant tumour is mostly denote by the adding of word 'sarcoma' (sarcos = fleshy) such as liposarcoma, fibrosarcoma, chondrosarcoma etc.

Classification of tumour on the basis of cell of origin
No.	Tissue of origin	Benign	Malignant
A. Epithelial tissue
1.	Squamous epithelium	Squamous cell papilloma	Squamous cell (epidermoid) carcinoma
2.	Transitional epithelium	Transitional cell papilloma	Transitional cell carcinoma
3.	Glandular epithelium	Adenoma	Adenocarcinoma
4.	Basal cell layer skin	----	Basal cell carcinoma
B. Connective tissue
6.	Adipose tissue	Lipoma	Liposarcoma
7.	Fibrous tissue (adult)	Fibroma	Fibrosarcoma
8.	Fibrous tissue (embryonic)	Myxoma	Myxosarcoma
C. Skeletal tissue
9.	Cartilage	Chondroma	Chondrosarcoma
10.	Bone	Osteoma	Osteosarcoma
D. Muscular tissue
11.	Smooth muscles	Leiomyoma	Leiomyosarcoma
12.	Skeletal muscles	Rhabdomyoma	Rhabdomyosarcoma
E. Nervous tissue
13.	Nerve sheath	Neurilemmoma, neurofibroma	Neurogenic sarcoma
14.	Nerve cells	Ganglioneuroma	Neuroblastoma
F. Mixed tumour
15.	Salivary glands	Pleomorphic adenoma	Malignant mixed salivary tumour
G. Tumours of more than one germ cell layer
16.	Totipotent cells in gonads in embryonal rests	Mature teratoma	Immature teratoma

Classification of the basis of Clinical Features:

One is Benign and second is Malignant.

Contrasting features of Benign and Malignant tumour:

Contrasting features of benign and malignant tumour
No.	Features	Benign	Malignant
I.	Clinical and Gross features
1.	Boundaries	Encapsulated (spherical or ovoid in shape)	Irregular
2.	Surrounding tissue	Often compressed	Often invaded
3.	Size	Small	Larger
4.	Secondary changes	Less	More
II.	Microscopic features
1.	Pattern	Usually resembles the tissue of origin closely	Often poor resemblance to tissue of origin
2.	Basal Polarity	Retained	Lost
3.	Pleomorphism	Usually absent	Present
4.	Nucleo-cytoplasmic ratio	Normal (1:5)	Increased (1:1)
5.	Anisonucleosis	Absent	Present
6.	Hyperchromatism	Absent	Present
7.	Mitoses	Typical mitoses	Atypical and abnormal mitoses
8.	Tumour giant cells	May be present but without nuclear atypia	Present with nuclear atypia
9.	Function	Usually well-maintained	May be retained, lost or become abnormal
III.	Growth rate	Slow	Rapid
IV.	Local invasion	Compresses the surrounding tissue without invading	Infiltrate and invade the adjacent tissue
V.	Metastasis	Absent	Present
VI.	Prognosis	Local complications	Death by local and metastatic complications

CHARACTERISTICS OF TUMOURS

1. Rate of Growth

2. Cancer Phenotype and Stem Cells

3. Clinical and Gross Features

4. Microscopic Features

5. Spread of tumours

Complete Anatomy of Liver

2024-10-09T16:08:00.002+05:30

Liver

Liver is the largest internal organ of the body.
Liver is the largest exocrine gland of the body.
Liver is the main heat producing organ of the body.
1500 ml/min blood pass-out from the liver.
400 ml blood always present in the liver.
Chief cells of the liver are called hepatocyte which forms 80% mass of the liver.

In this article we are discussing about on these topics...

Synonym
Location
Measurement
Presenting parts
Relation
Ligaments
Porta hepatis
Hepatic segments
Histology
Functions
Blood supply
Lymphatic drainage
Nerve supply
Applied anatomy

Front view of the liver

Synonym

Haper, hepta, biochemical lab, kitchen of the body.

Location

Right and left hypochondriac region and epigastric region.

Posterior and inferior view of the liver

Measurements

Weight - 1200 - 1500gms ( male - 1400-1600, female - 1200 - 1400gms)

Length - 26cm in male and 25cm in female average
Thickness - 22cm in adult male and 21cm in adult female average
Height - 7cm average
Color - Reddish brown
Consistency - soft
Quantity - one in number
Shape - wedge shape

Presenting parts

Surfaces ( 5 ) - Superior, Inferior, Anterior, Posterior, Right.

Border - Inferior

Lobes -

a. Necessary lobes - Right lobe and left lobe.

b. Accessory lobes - Caudate and quadrate lobe.

Surfaces

Superior surface

It is quadrilateral and shows a concavity in the middle called cardiac impression

Inferior surface

It is quadrilateral and is directed downwards and down to the left. Gastric impression, fissure for ligamentum teres, quadrate lobe, fossa for gallbladder and colic impression on it,

Anterior surface

It is triangular and slightly convex. Falciform ligament is attached on it.

Posterior surface

It is triangular and middle part of this surface shows a concavity for vertebral column. Bare area, groove for inferior vena cava, caudate lobe, fissure for ligamentum venosum and oesophageal impression.

Right surface

It is quadrilateral and convex. it is related to the diaphragm opposite to the 7th to 11th ribs in the mid axillary line.

Border

Inferior border

It is sharp anteriorly and interlobar notch for ligamentum teres and a cystic notch for the fundus for gallbladder present on it.

Lobes

Liver is divided into two lobes (right and left ) by the falciform ligament anteriorly and superiorly, fissure for ligamentum teres inferiorly and fissure for ligamentum venosum posteriorly.

Right lobe

It is much larger than the left lobe and forms 5/6 part of the liver. caudate (posterior surface) and quadrate (inferior surface ) lobe present on it.

Caudate lobe

it is situated on the posterior surface.

Quadrate lobe

It is situated on the inferior surface.

Left lobe

It is the much smaller than the right lobe and forms 1/6 part of the liver. tuber omentale or omental tuberosity present on it.

Relation

a. Peritoneal relation

Most of the liver is covered by the peritoneum except triangular bare area, groove for inferior vena cava, fossa for gallbladder, area attachment for lesser omentum and ligamentum venosum.

b. Visceral realation

Anteriorly

Xiphoid process, anterior abdominal wall, diaphragm and falciform ligament,

Posteriorly

Inferior vena cava, ligamentum venosum, abdominal part of oesophagus, bare area and caudate lobe.

Superiorly

Diaphragm

Inferiorly

Stomach, ligamentum teres and quadrate lobe.

Relations of Posterior and inferior surface of the liver

Right

Diaphragm and mid axillary line.

Ligaments

a. True ligaments

I. Ligamentum venosum (posteriorly) - remnant part of the ductus venosum.

II. Ligamentum teres (inferiorly) - remnant part of the umbilical cord. It is also called round ligament of the liver.

b. False ligaments

These are peritoneal folds.

These are 5 in number...

I. Falciform ligament

II. Coronary ligament

III. Right triangular ligament

IV. Left triangular ligament

V. Lessor omentum

Porta heapatis

It is also called as gateway of liver.

It situated on the posteroinferior surface of right lobe of the liver.

It's length about 5cm.

Portal vein and hepatic artery passes through it.

Hepatic segments

On the basis of intrahepatic distribution of the hepatic artery, portal vein and biliary duct, liver can be divided right and left functional lobes. These lobe don't correspond to the anatomical lobes.

Right anatomical lobe is sub divided into these hepatic segments...

Right anterior ( V and VIII )
Right posterior ( VI and VII )

Left anatomical lobe are sub divided into these hepatic segments...

Left lateral ( II and III )
Left medial ( I and IV )

Segments of the liver

Histology

Histology of liver (a). Portal lobule, (b). Liver acinus

Histology of the liver

Functions

Metabolism - carbohydrates, fats and proteins.
Synthesis - bile and prothrombin.
Excretion - drugs, toxins, poisons, cholesterol, bile pigments, and heavy metals.
Protective - conjugation, destruction, phagocytosis, antibody formation and excretion.
Storage - glycogen, fat, vitamins ( A,D,E,K and B12 ) and minerals ( iron ).

Blood supply

Arterial supply -

Hepatic artery - 20% blood supply for it.
Portal vein - 80% blood supply for it.

Venous drainage -

Hepatic vein

Blood supply of the liver

Lymphatic drainage

The liver produce a large amount of lymph which is estimated 25 - 50% of total lymph.

Hepatic lymph node
Paracardial lymph node
coeliac lymph node
Thoracic duct
Caval

Nerve supply

Hepatic nervous plexus which contain sympathetic and parasympathetic nerve fibers.

Sympathetic fibers - celiac plexus
Parasympathetic fibers - vagal fibers.

Clinical Anatomy of the Liver

Location and Examination: The liver is located in the infrasternal angle and can be examined through percussion, although it is usually not palpable due to the tone of the recti muscles and its softness.
Position: In the median plane, the lower border of the liver lies on the transpyloric plane, about a hand’s breadth below the xiphisternal joint. In women and children, this border often projects slightly below the right costal margin.
Liver Enlargement: The liver may enlarge towards the right iliac fossa. The spleen can also enlarge in the same direction.
Inflammation (Hepatitis): Liver inflammation, known as hepatitis, can be infective or amoebic.
Cirrhosis: In cases of malnutrition, liver tissue may undergo fibrosis and shrink, leading to cirrhosis.
Liver Biopsy: A liver biopsy is performed by inserting a needle through the right 9th intercostal space, passing through both the pleural and peritoneal cavities.
Metastasis: The liver is a common site for metastatic tumors, as venous blood from the gastrointestinal tract drains into the liver via the portal vein.
Blood Supply: The liver receives blood from both the hepatic artery and the portal vein, which lie in the free margin of the lesser omentum. Bleeding can be controlled by compressing this area (Pringle’s maneuver).
Liver Resection and Regeneration: Up to 80% of the liver can be safely removed during surgery, with the liver capable of regenerating within 6-12 months.
Liver Transplantation: Liver transplants involve grafting an organ from a donor, with various anastomoses of the veins, arteries, and bile ducts. A partial liver from a healthy donor can also be transplanted.
Portal Hypertension: In severe cases, procedures like TIPS (transjugular intraparenchymal portosystemic shunt) are used to reduce portal hypertension.
Cirrhosis Symptoms: Advanced cirrhosis can lead to "caput medusae," where distended veins are visible around the umbilicus.

Images are copied from BD chourasia and Tortora books

Sweet syndrome

2024-09-17T19:02:00.005+05:30

Sweet Syndrome (Acute Febrile Neutrophilic Dermatosis)

What is Sweet Syndrome?

Sweet Syndrome is a skin condition that causes painful, red or purple bumps and patches. It usually appears on the face, neck, and arms, and is often accompanied by fever and high levels of neutrophils in the blood.

Types of Sweet Syndrome:

1. Classic Sweet Syndrome: The most common form, often affecting young women, usually following mild illnesses or linked to pregnancy, inflammatory diseases, or infections.

2. Malignancy-Associated Sweet Syndrome: This type is connected to cancer, especially blood cancers like leukemia, and may even be the first sign of an underlying cancer.

3. Drug-Induced Sweet Syndrome: Caused by medications like granulocyte colony-stimulating factor (G-CSF), antibiotics, or cancer treatments.

Causes:

Classic: Often no clear cause, but can be triggered by infections, pregnancy, or inflammation.
Malignancy-Associated: Linked to cancers, especially leukemia.
Drug-Induced: Triggered by medications, including some cancer treatments.

Symptoms:

Painful red or purple bumps on the skin.
Fever and tiredness.
Sometimes linked to other conditions like infections or cancer.
Can affect other organs like the lungs, kidneys, or nervous system.

Diagnosis:

Doctors diagnose Sweet Syndrome based on the sudden appearance of painful skin lesions, fever, and lab tests showing high white blood cell counts. A skin biopsy (small tissue sample) may also be done to confirm the condition.

Treatment:

Steroids (like prednisone) are the main treatment, and they work quickly to relieve symptoms.
Other medications like colchicine or dapsone may be used for recurring or resistant cases.
If a drug is causing the condition, stopping the medication usually helps.

Prognosis:

Most cases improve with treatment, but Sweet Syndrome can come back, especially if linked to cancer. The outcome depends on treating the underlying cause if there is one.

In summary, Sweet Syndrome is a treatable condition often associated with infections, medications, or cancer, and it primarily affects the skin but can involve other organs.

For more about sweet syndrome

Dengue Fever

2023-12-19T18:30:00.001+05:30

DENGUE FEVER

Contents:

Introduction
Clinical presentation
Diagnosis
Treatment
Diet

Introduction:

Dengue fever is a viral infection caused by dengue virus.
Dengue virus is an RNA virus of genus flavi virus.
There are four serotypes dengue virus that is DENV-1, DENV-2, DENV-3, DENV-4
Dengue virus transmitted by Aedes aegypti mosquito

Aedes aegypti mosquito

Aedes aegypti mosquito known to transmit Dengue virus, Yellow fever virus, Chikungunya virus, and Zika virus and it also suggest as a potential vector of Venezuelan Equine Encephalitis virus and studies shown it is capable to transmit West Nile virus as well.

Clinical Presentation:

Divides into 4 categories :

Dengue without warning sign
Dengue with warning sign
Severe dengue / dengue hemorrhagic fever
Dengue shock syndrome

Remember Note:

Not all patient goes in all these phases.
Majority of patient develops dengue without warning sign and they cure self or general treatment.
But few patients who are not manage properly or the patient who are immunocompromised and who have weak immune system, they can progress from dengue without warning sign to dengue shock syndrome.

Dengue without warning sign:

Incubation period 4-10 days (2-14 days)
High grade fever 40˚C (104˚f)

Following any of two are present

Severe headache
Retro orbital pain
Myalgia, arthralgia (break bone fever)
Maculopapular widespread rashes.
Generalised lymphadenopathy.

Dengue with warning sign

Critical period begins -

3-7 days after symptoms onset

Warning signs appear after fever subsides

Population who are at risk –

Pt. with severe comorbidities
Infants less than 1 year of age
History of previous or recurrent dengue infection.

Warning Signs Include:

Abdominal pain with or without tenderness.
Persistent vomiting (>3 times in 24 hours)
Bleeding from nose or gums.
Blood in vomiting or blood in stool or blood in urine.
Lethargy, restlessness, irritable.
Enlarge liver > 2 cm

Severe Dengue / Dengue haemorrhagic fever

Re-infected with different serotype

This phase begins after fever subside

Temperature (hypothermia to second fever spike)

Plasma leak resulting in pleural effusion, ascites, haematocrit drops

Hemorrhagic manifestations such as gingival bleed, epistaxis, petechiae, ecchymosis, purpura, thrombocytopenia,

Severe organ involvement like hepatomegaly, liver failure

Changes in mental status - confusion

Petechiae and Purpura

Ecchymosis

Gingival Bleeding

Dengue Shock Syndrome

Severe hemorrhagic dengue

Shock (circulatory collapse)

Severe hemorrhagic fever with circulatory collapse is called dengue shock syndrome

It is fatal if not manage properly

Diagnosis

Serologic test to detect IgM (Initial 3-4 days the antibodies will be negative but patient having infection.

NAAT to detect viral RNA

NS-1 antigen to detect dengue non structural protein 1 (NS 1 antigen can be detected directly after onset of symptoms, before even IgM production begins)

Positive capillary fragility test.

When test become positive

TOURNIQUET FRAGILITY TEST –

Tourniquet applied to arm. Inflated to a point b/w systolic and diastolic pressure for 5 minutes.

Positive test : If 10 or more petechiae appear per square inch on forearm.

Treatment Approache

Don’t do this

Don’t use corticosteroids due to increase risk of GI bleeding, hyperglycemia.

Do not give platelet transfusion for low platelet count b/c it leads to fluid overload.

Do not assume that IV fluid are necessary, use minimum amount of IV fluid to keep patient profused.

Do not give ½ NS b/c it leads to ascites, pleural effusion etc.

You can do this

Do recognize the clinical period

Monitor fluid intake output, vital sign HCT level etc.

Do administer colloids such as albumin for refractory shock who do not responds 2-3 boluses of isotonic saline.

Do give PRBCs or whole blood for significant bleeding.

Dengue without warning sign Treatment approach

Paracetamol, cold sponging for fever (don’t give aspirin, ibuprofen)

Prevent dehydration (oral fluid – ORS)

Dengue with warning sign treatment approache

Admit in hospital

Check hematocrit value

If oral fluid intake inadequate give isotonic crystalloid (normal saline, RL)

Stepwise manner, 5-7ml/kg/hour for 1-2 hours followed by 3-5ml/kg/hour for 2-4 hours (increase rate if vital signs worsening.

Control fever with paracetamol and cold sponging.

Continue monitor – Haematocrit, fluid intake urine output, vital signs

Severe Dengue / Dengue haemorrhagic fever

Admit patient for emergency management.

Monitor fluid intake/output

Give controlled fluid 5-7ml/kg/hr for 1-2 hours, 3-5ml/kg/hr for next 2-4 hours, 2-3ml/kg for next 2-4 hours.

Check haematocrit level

DECREASING

Transfusion 5-10ml/kg PRBCs.

10-20ml/kg whole blood immediately

INCREASING

Give controlled crystalloid (NS, RL) 10-20 ml/kg bolous over 1 hour

Dengue Shock Syndrome

If patient have hypotensive shock: Give isotonic crystalloid or colloid bolus 20ml/kg within 15 min.

If condition improve than continue crystalloid and colloid and slowly taper.

If condition not improve than check haematocrit.

If hematocrit decrease than transfuse 5-10ml/ kg PRBCs or 10-20ml/kg whole blood.

If hematocrit increase than give colloid 10-20ml/kg bolus over 30 min – 1 hour

What can we do at home

Cold sponging to control fever.

ORS to maintain hydration.

Papaya leaf juice/papaya to maintain or increase platelet count. Papaya leaf extract is good for digestion which contain papain and chympapain.

Avoid heavy work or routine work.

Increase fruits (specially citrus fruits) in diet.

What should eat

Vitamin-C : It has antiviral and anti-oxidative properties and it boost immunity and it help to absorb another helpful nutrients such iron from intestine. Sources – Orange, lemon, papaya, pineaple etc.

Vitamin-K : Sprouts, broccoli, and green leafy vegetables.

High-calorie foods: Milk, rice, potato etc.

Water

What should avoid to eat

Red or brown colored : Drink or food like chocolate, violet colored juices b/c it misleads the disease progression.

Caffeine : Energy drinks, coffee, tea b/c these act as diuretics which make difficult to maintain hydration.

Spicy foods : Avoid spicy foods b/c it stimulates the stomach for more acid production which may cause stomach or intestinal bleeding.

Fatty foods : Cheese, cuts, butter, deep fried food and avocado etc. Dengue fever reduces the capacity of digestion and which make difficult to digest for the stomach.

Nucleus

2020-08-31T09:45:00.002+05:30

Name :- Nucleus (Nucleus was first described by Robert Brown in 1831, and it's material stained by the basic dyes was given the name chromatin by Flemming.)

Properties :

It is the largest cellular organelle.
Generally located in the center of the cell but it may vary in some cells.
It's diameter is about 10µ to 22µ.
Mostly it is spherical in shape but it may vary in some cells.
Nucleus occupies about 10% of total volume of the cell.
It is present in all the cells in the body except RBCs.
The cells with nucleus called eukaryotes and without nucleus called prokaryotes.
Presence of nucleus is necessary for cell division.
Most of the cells have only one nucleus called uninucleated cells.
Few types of cells like skeletal muscle have many nuclei called multinucleated cells.

Structure Of Nucleus :

Nuclear membrane
Major components like nucleoplasm, chromatin, chromosomes and nucleolus.

1. Nuclear Membrane (NM) :

NM is double layered membrane called nuclear envelope, separates the nucleus from the cytoplasm.
NM is porous in nature, which allows the nucleoplasm to communicate with the cytoplasm.
Pores (diameter - 80-100 nm) of the NM are lined by protein molecules (after attachment of protein molecules, pores diameter may decrease 7-9 nm).
Small molecules and ions move through the pores by passive diffusion, while large molecules such as RNAs and proteins pass through the selectively active transport.
Outer membrane of NM is continue with membrane of endoplasmic reticulum (ER).
The space between two layered of NM is continue with the lumen of the ER.

2. Major Components : Such as nucleoplasm, chromatin, chromosomes and nucleolus ....

Nucleoplasm :

Nucleoplasm is a highly viscous fluid similar to cytoplasm.
It surrounds chromatin and nucleolus.
It contains nuclear matrix (dense fibrillar network of protein) and many substances such as nucleotides, enzymes and hyaloplasm (soluble liquid part of nucleoplasm).
Nuclear matrix forms the structural framework for organizing chromatin.

Chromatin :

Chromatin is a thread like material referred as DNA-histone complex or complex of DNA, proteins (histones) and some RNA. (A chain of nucleosomes)
DNA is a double helix which wraps around the central core of eight histone molecules to form the fundamental packing unit of chromatin called nucleosome. (Eight histones wrapped by double helix DNA)
Nucleosomes are packed together tightly with the help of histone molecule to form a chromatin fiber.
Just before cell division, the chromatin condenses to form a pair of chromatids that constitutes a chromosome.
In the cell that are not dividing, the chromatin appears as a diffuse granular mass.

Chromosomes :

Chromosome is the rod-shaped nuclear structure that carries a complete blueprint of all the hereditary characteristics of that species.
Each chromosome is a long molecule of DNA (contains many genes) that is coiled together with several proteins.
Normally, the chromosomes are not visible in the nucleus under microscope while it visible (because DNA more tightly packed just before cell division) only during cell division.
All the dividing cells of the body except reproductive cells contain 23 pairs of chromosomes.
Each pair consists of one chromosome inherited from father and one from mother.
The cells with 23 pairs of chromosomes are called diploid cells. The cells with 23 single chromosomes called haploid cells like reproductive cells also called for this gametes or sex cells.

Nucleolus (pleural - nucleoli) :

Nucleolus is a small, round granular structure of the nucleus.
Each nucleus contain one or more nucleoli.
Nucleoli are quite prominent in cells that synthesize large amount of protein like muscle and liver cells.
Nucleoli disperse and disappear during cell division and reorganize once new cells are formed.
The nucleolus contains RNA and some proteins which are similar to those found in ribosomes.
The RNA is synthesized by five different pairs of chromosomes and stored in nucleolus. Later, it condensed to form sub-units of ribosomes. All the sub-units are transported from nucleolus to cytoplasm through pores of the nuclear membrane.

Functions Of Nucleus :

Control of the all activities of the cell such as metabolism, protein synthesis, growth and reproduction (cell division).
Synthesis of RNA.
Formation of sub-units of ribosomes.
Sending genetic instruction to the cytoplasm for protein synthesis through messenger RNA (mRNA).
Control of the cell division through genes.
Storage of hereditary information (in genes) and transformation of this information from one generation of the species to the next.

Similar Posts :

Practical Medicine (P. J. Mehta's)

2020-07-30T10:37:00.000+05:30

Practical Medicine (P. J. Mehta's) 20th edition

PART-1 CLINICAL CASES

1. History Taking and Symptomatology

2. General Examination

3. Abdomen

4. Respiratory System

5. Cardiovascular System

6. Central Nervous System

PART-2 TABLE-WORK

7. Medical Emergencies

8. Electrocardiography

9. Radiology

10. Instruments

11. Procedures

12. Hematology

13. Clinical Pathology

14. Pathology Specimens

15. Drugs

ABOUT BOOK
Name Book	Practical Medicine (P. J. Mehta’s)
Author/ Editior (20^th edition)	SP Mehta, SR Joshi, Nihar P Mehta / Dr. Hardik shah, Dr. Sunita Iyer, Dr. Nikesh Jain, Dr. Rajiv Shah.
Type	pdf.
Size	69.47 MB
Pages	630
Pages type	Colored
Quality (Good/average/bad)	Good

Download Now

Similar Posts :-

1. Park’s Textbook of PSM

2. Review of Preventive and Social Medicine (Vivek Jain)

3. Medicine (Exam Preparatory manual for Undergraduates)

4. General Anatomy BD Chourasia

5. Medical Books

Golgi apparatus

2020-07-11T09:58:00.005+05:30

Name :- Golgi apparatus, Golgi body, Golgi complex, Post office of the cell, Shipping department of the cell (Camillo Golgi (1898) first discovered, hence the name is Golgi).

Properties :

It is an membrane bound organelle situated near the nucleus.
It is present in all cells except RBCs.
Usually, each cell has one Golgi apparatus.
Each Golgi apparatus consists of 5-8 flattened membranous sacs called cisternae (0.5-1.0 micrometer).
Golgi apparatus has two ends or faces, namely cis face (situated near the endoplasmic reticulum) and trans face (situated near the cell membrane).

Functions :

Major functions of Golgi apparatus are processing, packing, labeling and delivery of proteins and lipids to different part of the cell or outside of the cell.

Processing :- glycoproteins and lipids are modified here.
Packaging :- modified materials are packed in the form of secretory granules, secretory vesicles and lysosomes.
Labeling and delivery :- Golgi apparatus sort out the processed materials and labels them (such as phosphate group) then distribute in or out side of the cell according to demand.

Similar Posts :-

Tabes Dorsalis (Locomotor ataxia)

2020-05-10T22:10:00.000+05:30

There is slowly progressive degeneration of the posterior roots of the spinal nerves and the posterior column of the spinal cord by the spirochetes or demyelination of dorsal group of neurons. These changes produce loss of coordination of muscles and joints resulting in locomotor ataxia.

Cell Adaptation

2020-04-27T22:52:00.000+05:30

Adaptive Disorders

Definition :- Cell become change or adapt in response to adverse environmental changes that's called adaptation.

Types of adaptation

1. Atrophy (decrease cell size)

2. Dysplasia ( abnormal growth or development of cell )

3. Hyperplasia ( increase reproduction rate of the cell )

4. Hypertrophy ( increase cell size )

5. Metaplasia ( conversion of the cell from one type to another type e.g. squamus cell convert into columnar cell )

Adaptive Disorders

Difference between Metaplasia and Dysplasia

Similar Posts -

Dysplasia / Atypical hyperplasia

2020-04-27T22:23:00.000+05:30

Definition – It is the disordered cellular development associated with metaplasia and hyperplasia caused by chronic irritation and prolonged inflammation. It is occur most commonly in epithelial cells.

Dysplasia characterised by cellular proliferation and cytologic changes as under…

Increase number of layers of epithelial cells.
Disorderly arrangement of cells from basal layer to the surface layer.
Loss of polarity i.e. nuclei lying away from basement membrane.
Cellular and nuclear pleomorphism.
Increase nucleocytoplasmic ratio.
Nuclear hyperchromatism.
Increase mitotic activity.

Most common examples of dysplastic changes are the uterine cervix and respiratory tract.

Difference between Metaplasia and Dysplasia

Similar Posts -

Metaplasia

2020-04-27T22:07:00.000+05:30

Definition – Metaplasia is a reversible condition in which one type of epithelial or mesenchymal adult cells convert into another type of epithelial or mesenchymal cells, usually in response to abnormal stimuli and it reverts back after removal of stimulus. If stimulus persists for long time then metaplasia convert into dysplasia and further convert into cancer.

Types – (1) Epithelial metaplasia (2) Mesenchymal metaplasia

1. Epithelial metaplasia – This is the more common type in which metaplastic changes may be patchy or diffuse and usually replaced by stronger but less well-specialised epithelium. There are two types of epithelial metaplasia…

A. SQUAMOUS METAPLASIA – It is caused by chronic irritation that may be mechanical, chemical or infective in origin. Some common examples…

In bronchus (normally lined by pseudostratified columnar ciliated epithelium) in chronic smokers.
In uterine endocervix (normally lined by simple columnar epithelium) in prolapsed of the uterus and in old age.
In gallbladder (normally lined by simple columnar epithelium) in chronic cholecystitis and cholelithiasis.
In prostate (ducts normally lined by simple columnar epithelium) in chronic prostatitis and oestrogen therapy.
In renal pelvis and urinary bladder (normally lined by transitional epithelium) in chronic infection and stones.
In vitamin A deficiency (xerophthalmia) in nose, bronchi, urinary tract, lacrimal and salivary glands.

B. COLUMNAR METAPLASIA – There are some conditions in which there is transformation to columnar epithelium. For example_

Intestinal metaplasia in healed chronic gastric ulcer.
Columnar metaplasia in Barrett’s oesophagus (change squamous to columnar epithelium).
Pseudostratified ciliated columnar epithelium change into columnar epithelium in chronic bronchitis and bronchiectasis.

2. Mesenchymal metaplasia – Less often, there is transformation of one adult type of mesenchymal tissue to another. There is two types

A. OSSEOUS METAPLASIA – Formation of bone in fibrous tissue, cartilage and myxoid tissue. Examples…

In arterial wall in old age (Monckeberg’s medial calcific sclerosis).
In soft tissues in myositis ossificans.
In cartilage of larynx and bronchi in elderly people.
In scar of chronic inflammation of prolonged duration.

B. CARTILAGINOUS METAPLASIA – It may occur in healing of fractures, where there is undue mobility.

Differences between Metaplasia and Dysplasia

Similar Posts -

Hyperplasia

2020-04-27T20:41:00.000+05:30

Definition – Hyperplasia is an increase in the number of parenchymal cells resulting in enlargement of the organ or tissue. Quite often, both hyperplasia and hypertrophy occur together.

Causes – It may be physiological or pathological…

PHYSIOLOGICAL HYPERPLASIA –

1. Hormonal hyperplasia, it occurs due hormonal stimulation.

a. Hyperplasia of female breast at puberty, during pregnancy and lactation.

b. Hyperplasia of pregnant uterus.

c. Proliferative activity of normal endometrium after a normal menstrual cycle.

d. Prostatic hyperplasia in old age.

2. Compensatory hyperplasia i.e. it occurs due to removal of part of an organ or in the contralateral organ in paired organ e.g.

a. Regeneration of liver after partial hepatectomy.

b. Regeneration of epidermis after skin abrasion.

c. Hyperplasia of nephrons after another nephrectomy.

PATHOLOGICAL HYPERPLASIA – It is occurs due to excessive stimulation of hormones or growth factors e.g.

Endometrial hyperplasia due to excess oestrogen.
In wound healing, there is formation of granulation tissue due to proliferation of fibroblasts and endothelial cells.
Formation of skin warts from hyperplasia of epidermis due to human papilloma virus.
Pseudocarcinomatous hyperplasia of the skin occurring at the margin of a non-healing ulcer.
Intraductal epithelial hyperplasia in fibrocystic change in the breast.

MORPHOLOGICAL FEATURES –There is enlargement of the affected organ or tissue and increase in the number of cells due to increase DNA synthesis resulting in increase mitoses of the cells.

“Hyperplasia occurs in labile cells (epithelial cells of the skin, mucous membrane, lymph nodes, cells of bone marrow), stable cells (parenchymal cells of the liver, kidney, pancreas, adrenal, thyroid) while hyperplasia does not occurs in permanent cells (neurons, cardiac and skeletal muscles)”

Adaptive Disorders

Similar Posts -

Hypertrophy

2020-04-27T20:10:00.000+05:30

Hypertrophy

Definition – Hypertrophy is an increase in the size of parenchymal cells resulting in enlargement of the organ or tissue, without any change in the number of cells.

Causes – It may be physiological or pathological…

PHYSIOLOGICAL HYPERTROPHY – Enlarged size of uterus in pregnancy.

PATHOLOGICAL HYPERTROPHY –

Hypertrophy of cardiac muscles, e.g. systemic hypertension, aortic valve disease (stenosis and insufficiency), mitral insufficiency.
Hypertrophy of smooth muscles, e.g. cardiac achalasia (in oesophagus), pyloric stenosis (in stomach), intestinal strictures, muscular arteries in hypertension.
Hypertrophy of skeletal muscles, e.g. athletes and manual labourers.
Compensatory hypertrophy after removal of contralateral organ, e.g. nephrectomy, adrenal hyperplasia.

Cardiac Hypertrophy

MORPHOLOGICAL FEATURES – The affected organ is enlarged and heavy. There is enlargement of muscles fibres as well as of nuclei. At ultra-structural level, there is increased synthesis of DNA and RNA, protein and increased number of organelles such as mitochondria, endoplasmic reticulum and myofibrils.

Similar Posts -

Infarction

2020-04-27T19:49:00.001+05:30

Infarction

Definition – A necrotic area is called infarct and the process of infarct formation is called infarction.

Causes – Ischaemic necrosis (most common), stagnant hypoxia (venous obstruction), thrombosis, embolism, narrowing of the coronary artery (atherosclerosis) etc.

Types of infarcts –

1. According to colour …

a. Pale or anemic infarct – It is due to arterial occlusion, commonly seen in compact organ like heart, kidney and spleen.

b. Red or haemorrhagic infarct – It is due to obstruction of the artery, commonly seen in soft loose tissue e.g. lungs and intestine.

Haemorrhagic Infarct of the Lung

2. According to the age … Recent and old.

3. According to the presence or absence of the infection…

a. Bland – Free from bacterial contamination

b. Infected – Infected with bacterial contamination.

4. According to the type of action…

a. Bacteriostatic – It inhibit growth of bacteria e.g. tetracycline, erythromycin, sulfonamide etc.

b. Bactericidal – It kills bacteria e.g. refampicin, penicillin etc.

5. According to the spectrum of activity… narrow and broad spectrum.

PATHOGENESIS –

Localized hyperaemia or congestion may occur due to obstruction of blood supply.
Within few hours edema and haemorrhage may occur.
Cellular change such as cloudy swelling appear early, necrosis occur within 12-15 hours.
Progressive proteolysis of necrotic tissue and there is lysis of red cells.
Acute inflammatory reactions appear in surrounding tissue.
Blood pigments like haematoidin and haemosiderin deposit in the infarct.
Following this granulation tissue starts to appears at the margin, finally infarct is replaced by collagen fibers and a scar is formed.

GROSSLY – Infarcts of solid arms are usually wedge shaped with apex at the obstructed artery and base of the surface of the organ. Most infarcts become pale due to breakdown of red cells but pulmonary infarcts never become pale due to extensive blood supply.

Cerebral infarcts appear with central softening due to liquefaction necrosis (encephalomalacia), recent infarcts are generally slightly elevated over the surface but old infarcts are shrunken and depressed due to scar.

MICROSCOPICALLY – The tissue of affected area shows coagulation necrosis but in cerebral infarcts there is liquefaction necrosis. At the periphery of infarcts inflammatory reaction is noted. Finally the infarct is replaced by scar, but in cerebral infarcts there is gliosis.

Infarcts of most commonly affected organ

Similar Posts -

Haemorrhage

2020-04-27T16:39:00.000+05:30

Haemorrhage

Definition – Haemorrhage is the escape of blood from a blood vessel.

HAEMATOMA – Extravasation of blood into the tissue with resultant swelling is known as haematoma.

ECCHYMOSIS – Large extravasations of blood into the skin and mucous membranes are called ecchymosis.

PURPURA – Small areas of haemorrhage (up to 1 cm) into the skin and mucous membrane called purpura.

PETECHIAE – Minute pinhead size haemorrhages on the skin are called petechiae.

FORMS –

Epistaxis (nosebleed)
Haemoptysis (coughing up blood)
Haematemesis (vomiting blood)
Haematuria (blood in urine)
Melena (dark stool)
Polymenorrhea (short menstrual cycle <21 days)
Menorrhagia (heavy periods)
Postpartum haemorrhage (excessive bleeding after childbirth)
Antepartum haemorrhage (genital bleeding during pregnancy, third trimester to till birth or delivery)

Classification –

1. According to the nature or type … (a) External or visible haemorrhage (b) Internal or concealed haemorrhage.

2. According to the timing …

a. Primary haemorrhage – When haemorrhage occurs just after injury of vessels.

b. Reactionary haemorrhage – When bleeding within 24 hours (usually 4-6 hours) causing slipping of ligature, dislodgement of clot.

c. Secondary haemorrhage – When haemorrhage occurs after 7-14 days causing surgery, sloughing of vessels due to infection.

3. According to the source…

a. Arterial haemorrhage – When bleeding occurs due to rupture of artery. Blood is bright red in colour and emitted as spurting jet.

b. Venous haemorrhage – When bleeding occurs due to rupture of veins. Blood is dark red in colour and emitted steady and copious flow.

c. Capillary haemorrhage – When bleeding occurs due to rupture of capillaries. Blood is bright red in colour and emitted rapid oozing.

4. According to the duration … (a) Acute haemorrhage (b) Chronic haemorrhage

5. According to the type of intervention… (a) Surgical (b) Non-surgical haemorrhage

Effects of Haemorrhage –

33% of total blood, sudden loss may cause death.
50% of total blood, loss over the period of 24 hours may not necessary fatal.
Chronic haemorrhage generally produce iron deficiency anaemia while occur acute haemorrhage may cause hypovolaemic shock.

Etiology –

Trauma to the vessel wall, e.g. penetrating wound in the heart or great vessels.
Spontaneous haemorrhage, e.g. rupture of an aneurism, septicaemia, bleeding diathesis, acute leukaemias, pernicious anaemia, scurvy.
Inflammatory lesions of the vessel wall, e.g. bleeding from chronic peptic ulcer, typhoid ulcers, traversing a tuberculous cavity in the lung, syphilitic involvement of the aorta, polyarteritis nodosa.
Neoplastic invasion, e.g. vascular invasion in carcinoma of the tongue.
Vascular disease, e.g. atherosclerosis.
Elevated pressure within the vessels, e.g. cerebral and retinal haemorrhage in systemic hypertension, severe haemorrhage from varicose veins due to high blood pressure in the veins of legs or oesophagus.

Similar Posts -

Aas_Study

Endomyocardial Fibrosis

Endomyocardial Fibrosis

Causes & Risk Factors

Pathogenesis

Symptoms & Signs

Diagnosis

Treatment

Allopathic Management:

Homeopathic Approach:

Ayurvedic Therapy:

Unani Remedies:

Prevention

Complications

Prognosis

Epidemiology

Research & Recent Advances

Case Studies

Summary & Conclusion

References

Endocardial Fibroelastosis

Endocardial Fibroelastosis

Causes & Risk Factors

Pathogenesis

Symptoms & Signs

Diagnosis

Treatment

Prevention

Complications

Prognosis

Epidemiology

Research & Recent Advances

Case Studies

Summary & Conclusion

References

Cardiac Amyloidosis

Cardiac Amyloidosis: An In-Depth Analysis

Aetiology and Risk Factors

Pathophysiology

Clinical Presentation

Diagnostic Approach

Therapeutic Strategies

Prevention and Risk Reduction

Disease Complications

Prognosis

Epidemiological Trends

Recent Advances in Research

Case Studies

Case Study 1: AL Amyloidosis

Case Study 2: ATTR Amyloidosis

Conclusion

References

Dilated Cardiomyopathy

Idiopathic Dilated or Congestive Cardiomyopathy: A Comprehensive Guide

Types and Classification

Causes and Risk Factors

Pathophysiology

Signs and Symptoms

Diagnosis

Stages or Progression

Treatment Options

Complications

Prognosis

Prevention

Living with the Disease

FAQs

Conclusion

Obstructive Cardiomyopathy

Obstructive Cardiomyopathy: A Comprehensive Overview

Pathophysiology

Etiology and Risk Factors

Clinical Manifestations

Diagnostic Evaluation

Complications

Therapeutic Approaches

Long-Term Management and Prognosis

Preventative Measures

Coping with HOCM

Conclusion

References